

LIST OF PUBLICATIONS

DARIUS MORADPOUR

Original articles

1. **Moradpour D**, Compagnon B, Nicolau C, Wands JR. Specific targeting of human hepatocellular carcinoma cells by immunoliposomes *in vitro*. *Hepatology* 1995;22:1527-1537.
2. **Moradpour D**, Wakita T, Tokushige K, Carlson RI, Krawczynski K, Wands JR. Characterization of three novel monoclonal antibodies against hepatitis C virus core protein. *J Med Virol* 1996;48:234-241.
3. **Moradpour D**, Schauer JI, Zurawski VR Jr, Wands JR, Boutin RH. Efficient gene transfer into mammalian cells with cholesteryl-spermidine. *Biochem Biophys Res Commun* 1996;221:82-88.
4. Tokushige K, Wakita T, Pachuk C, **Moradpour D**, Weiner DB, Zurawski VR Jr, Wands JR. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. *Hepatology* 1996;24:14-20.
5. **Moradpour D**, Englert C, Wakita T, Wands JR. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. *Virology* 1996;222:51-63.
6. Heller R, Jaroszeski M, Atkin A, **Moradpour D**, Gilbert R, Wands JR, Nicolau C. In vivo targeted gene transfer and expression using direct electroporation. *FEBS Lett* 1996;389:225-228.
7. Tokushige K, **Moradpour D**, Wakita T, Geissler M, Hayashi N, Wands JR. Comparison between cytomegalovirus promoter- and elongation factor 1 α promoter-driven constructs in the establishment of stable HCV core expressing cell lines. *J Virol Methods* 1997;64:73-80.
8. Compagnon B, **Moradpour D**, Alford DR, Larsen CE, Stevenson MJ, Wands JR, Nicolau C. Enhanced gene delivery and expression in human hepatocellular carcinoma cells by cationic immunoliposomes. *J Liposome Res* 1997;7:127-141.
9. da Silva Cardoso M, Siemoneit K, Sturm D, Krone C, **Moradpour D**, Kubanek B. Isolation and characterization of human monoclonal antibodies against hepatitis C virus envelope glycoproteins. *J Med Virol* 1998;55:28-34.
10. **Moradpour D**, Wakita T, Wands JR, Blum HE. Tightly regulated expression of the entire hepatitis C virus structural region in continuous human cell lines. *Biochem Biophys Res Commun* 1998;246:920-924.
11. Yasui K, Wakita T, Tsukiyama-Kohara K, Funahashi S, Ichikawa M, Kajita T, **Moradpour D**, Wands JR, Kohara M. The native form and maturation process of hepatitis C virus core protein. *J Virol* 1998;72:6048-6055.
12. **Moradpour D**, Kary P, Rice CM, Blum HE. Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins. *Hepatology* 1998;28:192-201.
13. **Moradpour D**, Englert C, Blum HE. Independent regulation of two separate gene activities in a continuous human cell line. *Biol Chem* 1998;379:1189-1191.
14. Chemin I, **Moradpour D**, Wieland S, Offensperger WB, Walter E, Behr J-P, Blum HE. Liver-directed gene transfer: a linear polyethylenimine derivative mediates highly efficient DNA delivery to primary hepatocytes *in vitro* and *in vivo*. *J Viral Hepat* 1998;5:369-375.

15. Duvet S, Pillez A, Cocquerel L, Cacan R, Verbert A, **Moradpour D**, Wychowski C, Dubuisson J. Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. *J Biol Chem* 1998;273:32088-32095.
16. Mohr L, Schauer JI, Boutin RH, **Moradpour D**, Wands JR. Targeted gene transfer to hepatocellular carcinoma cells *in vitro* using a novel monoclonal antibody-based gene delivery system. *Hepatology* 1999;29:82-89.
17. Tang Z-Y, Köck J, **Moradpour D**, Yang D-L, Hao L-J, Blum HE. Hepatitis G virus infection in Chinese patients with chronic hepatitis B, C or non-A-E: clinical and molecular aspects. *Hepatol Res* 1999;13:133-142.
18. Wakita T, **Moradpour D**, Tokushige K, Wands JR. Specific inhibition of hepatitis C virus gene expression by antisense RNA constructs *in vitro* and in cell culture. *J Med Virol* 1999;57:217-222.
19. Polyak SJ, Paschal D, McArdle S, Gale M Jr, **Moradpour D**, Gretch DR. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. *Hepatology* 1999;29:1262-1271.
20. Heim HM, **Moradpour D**, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. *J Virol* 1999;73:8469-8475.
21. Wölk B, Sansonno D, Kräusslich HG, Dammacco F, Rice CM, Blum HE, **Moradpour D**. Subcellular localization, stability, and *trans*-cleavage competence of the hepatitis C virus NS3-4A complex expressed in tetracycline-regulated cell lines. *J Virol* 2000;74:2293-2304.
22. François C, Duverlie G, Rebouillat D, Khorsi H, Castelain S, Blum HE, Gatignol A, Wychowski C, **Moradpour D**, Meurs EF. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of the PKR-mediated control of protein synthesis. *J Virol* 2000;74:5587-5596.
23. Thoma C, Wieland S, **Moradpour D**, von Weizsäcker F, Offensperger S, Madon J, Blum HE, Offensperger WB. Ligand-mediated retargeting of recombinant adenovirus for gene transfer *in vivo*. *Gene Ther* 2000;7:1039-1045.
24. Beuschlein F, Strasburger CJ, Siegerstetter V, **Moradpour D**, Lichter P, Bidlingmaier M, Blum HE, Reincke M. Acromegaly caused by secretion of growth hormone by a non-Hodgkin's lymphoma. *N Engl J Med* 2000;342:1871-1876.
25. Frese M, Pietschmann T, **Moradpour D**, Haller O, Bartenschlager R. Interferon- α inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. *J Gen Virol* 2001;82:723-733.
26. **Moradpour D**, Grabscheid B, Kammer A, Schmidtke G, Groettrup M, Blum HE, Cerny A. Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation *in vitro*. *Hepatology* 2001;33:1282-1287.
27. Hügler T, Fehrmann F, Bieck E, Kohara M, Kräusslich H-G, Rice CM, Blum HE, **Moradpour D**. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. *Virology* 2001;284:70-81.
28. Schmidt-Mende J, Bieck E, Hügler T, Penin F, Rice CM, Blum HE, **Moradpour D**. Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. *J Biol Chem* 2001;276:44052-44063.

29. **Moradpour D**, Bieck E, Hügler T, Wels W, Wu JZ, Hong Z, Blum HE, Bartenschlager R. Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase. *J Biol Chem* 2002;277:593-601.
30. Brass V, Bieck E, Montserret R, Wölk B, Hellings JA, Blum HE, Penin F, **Moradpour D**. An aminoterminal amphipathic α -helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. *J Biol Chem* 2002;277:8130-8139.
31. Egger D, Wölk B, Gosert R, Bianchi L, Blum HE, **Moradpour D**, Bienz K. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. *J Virol* 2002;76:5974-5984.
32. Ivashkina N, Wölk B, Lohmann V, Bartenschlager R, Blum HE, Penin F, **Moradpour D**. The hepatitis C virus RNA-dependent RNA polymerase membrane insertion sequence is a transmembrane segment. *J Virol* 2002;76:13088-13093.
33. Blindenbacher A, Duong F, Hunziker L, Stutvoet STD, Wang X, Terracciano L, **Moradpour D**, Blum HE, Alonzi T, Tripodi M, La Monica N, Heim MH. Expression of hepatitis C virus proteins inhibits interferon- α signaling in the liver of transgenic mice. *Gastroenterology* 2003;124:1465-1475.
34. Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, **Moradpour D**. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. *J Virol* 2003;77:5487-5492.
35. Gremion C, Grabscheid B, Wölk B, **Moradpour D**, Reichen J, Pichler W, Cerny A. Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells *via* Fas-FasL interaction. *J Virol* 2004;78:2152-2157.
36. **Moradpour D**, Evans MJ, Gosert R, Yuan ZH, Blum HE, Goff SP, Lindenbach BD, Rice CM. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. *J Virol* 2004;78:7400-7409.
37. Penin F, Brass V, Appel N, Ramboarina S, Montserret R, Ficheux D, Blum HE, Bartenschlager R, **Moradpour D**. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. *J Biol Chem* 2004;279:40835-40843.
38. Engler OB, Schwendener RA, Dai WJ, Wölk B, Pichler W, **Moradpour D**, Brunner T, Cerny A. A liposomal peptide vaccine inducing CD8⁺ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus proteins. *Vaccine* 2004;23:58-68.
39. **Moradpour D**, Brass V, Bieck E, Friebe P, Gosert R, Blum HE, Bartenschlager R, Penin F, Lohmann V. Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication. *J Virol* 2004;78:13278-13284.
40. Wölk B, Gremion C, Ivashkina N, Engler OB, Grabscheid B, Bieck E, Blum HE, Cerny A, **Moradpour D**. Stable human lymphoblastoid cell lines constitutively expressing hepatitis C virus proteins. *J Gen Virol* 2005;86:1737-1746.
41. Gosert R, Jendrszok W, Berke JM, Brass V, Blum HE, **Moradpour D**. Characterization of nonstructural protein membrane anchor deletion mutants expressed in the context of the hepatitis C virus polyprotein. *J Virol* 2005;79:7911-7917.
42. Meylan E, Curran J, Hofmann K, **Moradpour D**, Binder M, Bartenschlager R, Tschopp J. Cardif is a novel adaptor protein in RIG-I-mediated antiviral responses targeted by hepatitis C virus. *Nature* 2005;437:1167-1172.

43. Duong FHT, Christen V, Berke JM, **Moradpour D**, Heim MH. Upregulation of protein phosphatase 2A by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase I. *J Virol* 2005;79:15342-15350.
44. Sapay N, Montserret R, Chipot C, Brass V, **Moradpour D**, Deléage G, Penin F. NMR structure and molecular dynamics of the in-plane membrane anchor domain of nonstructural protein 5A from bovine viral diarrhea virus. *Biochemistry* 2006;45:2221-2233.
45. Combet C, Charavay C, Grando D, Crisan D, Lopez J, Garnier N, Geourjon C, Bettler E, Hulo C, Bairoch A, Bartenschlager R, Diepolder H, **Moradpour D**, Pawlotsky J-M, Rice CM, Trépo C, Penin F, Deléage G. euHCVdb: the European Hepatitis C Virus Database. *Nucleic Acids Res* 2007;35:D363-366.
46. Brass V, Pal Z, Sapay N, Deléage G, Blum HE, Penin F, **Moradpour D**. Conserved determinants for membrane association of nonstructural protein 5A from hepatitis C virus and related viruses. *J Virol* 2007;81:2745-2757.
47. Piccoli C, Scrima R, Quarato G, D'Aprile A, Ripoli M, Lecce L, Boffoli D, **Moradpour D**, Capitanio N. Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. *Hepatology* 2007;46:58-65.
48. Brass V, Berke JM, Montserret R, Blum HE, Penin F, **Moradpour D**. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. *Proc Natl Acad Sci USA* 2008;105:14545-14550.
49. Ji J, Glaser A, Wernli M, Berke JM, **Moradpour D**, Erb P. Suppression of short interfering RNA-mediated gene silencing by the structural proteins of hepatitis C virus. *J Gen Virol* 2008;89:2761-2766.
50. Wölk B, Büchele B, **Moradpour D***, Rice CM*. A dynamic view of hepatitis C virus replication complexes. *J Virol* 2008;82:10519-10531. *Joint corresponding authors.
51. Kazadi K, Loeuillet C, Deutsch S, Beckmann J, **Moradpour D**, Antonarakis S, Telenti A. Genomic determinants of the efficiency of internal ribosome entry sites of viral and cellular origin. *Nucleic Acids Res* 2008;36:6918-6925.
52. Piccoli C, Quarato G, Ripoli M, D'Aprile A, Scrima R, Cela O, Boffoli D, **Moradpour D**, Capitanio N. HCV infection induces mitochondrial bioenergetic unbalance: causes and effects. *Biochim Biophys Acta* 2009;1787:539-546.
53. Gouttenoire J, Castet V, Montserret R, Arora N, Raussens V, Ruyschaert J-M, Diesis E, Blum HE, Penin F, **Moradpour D**. Identification of a novel determinant for membrane association in hepatitis C virus nonstructural protein 4B. *J Virol* 2009;83:6257-6268.
54. Bellecave P, Gouttenoire J, Gajer M, Brass V, Koutsoudakis G, Blum HE, Bartenschlager R, Nassal M, **Moradpour D**. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. *Hepatology* 2009;50:46-55.
55. Bochud PY, Cai T, Overbeck K, Bochud M, Rickenbach M, Dufour JF, Müllhaupt B, Borovicka J, Heim M, **Moradpour D**, Cerny A, Malinverni R, Francioli P, Negro F, on behalf of the Swiss Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. *J Hepatol* 2009;51:655-666.
56. Gouttenoire J, Montserret R, Kennel A, Penin F, **Moradpour D**. An amphipathic α -helix at the C terminus of hepatitis C virus nonstructural protein 4B mediates membrane association. *J Virol* 2009;83:11378-11384.

57. Ripoli M, D'Aprile A, Quarato G, Sarasin-Filipowicz M, Gouttenoire J, Scrima R, Cela O, Boffoli D, Heim MH, **Moradpour D**, Capitanio N, Piccoli C. Hepatitis C virus-linked mitochondrial dysfunction promotes hypoxia-inducible factor 1 α -mediated glycolytic adaptation. *J Virol* 2010;84:647-660.
58. Overbeck K, Dufour J-F, Müllhaupt B, Helbling B, Borovicka J, Malinverni R, Heim M, **Moradpour D**, Cerny A, Rickenbach M, Negro F, on behalf of the Swiss Hepatitis C Cohort Study Group. Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland. *Swiss Med Wkly* 2010;140:146-152.
59. Bellecave P, Sarasin-Filipowicz M, Donzé O, Kennel A, Gouttenoire J, Meylan E, Terracciano L, Tschopp J, Sarrazin C, Berg T, **Moradpour D***, Heim MH*. Cleavage of MAVS in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. *Hepatology* 2010;51:1127-1136. *Joint last and corresponding authors.
60. Rauch A, Kutalik Z, Descombes P, Cai T, di Julio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Calandra T, Colombo S, Cerny A, Dufour J-F, Furrer H, Günthardt HF, Heim M, Hirschel B, Malinverni R, **Moradpour D**, Müllhaupt B, Witteck A, Beckman J, Berg T, Bergman S, Negro F, Telenti A, Bochud P-Y, and the Swiss Hepatitis C and HIV Cohort Studies. Genetic variation in *IL28B* is associated with chronic hepatitis C and treatment failure - a genome-wide association study. *Gastroenterology* 2010;138:1338-1345.
61. De Gottardi A, Hilleret M-N, Gelez P, La Mura V, Guillaud O, Majno P, Hadengue A, Morel P, Zarski J-P, Fontana M, **Moradpour D**, Mentha G, Boillot O, Leroy V, Giostra E, Dumortier J. Injection drug use before and after liver transplantation: a retrospective multicenter analysis on incidence and outcome. *Clin Transplant* 2010;24:564-571.
62. Brass V, Gouttenoire J, Wahl A, Pal Z, Blum HE, Penin F, **Moradpour D**. Hepatitis C virus RNA replication requires a conserved structural motif within the transmembrane domain of the NS5B RNA-dependent RNA polymerase. *J Virol* 2010;84:11580-11584.
63. Sgier C, Müllhaupt B, Gerlach T, **Moradpour D**, Negro F, Malé J, Heim M, Malinverni R, Cerny A, Dufour J-F. Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C. *J Viral Hepat* 2010;17:845-850.
64. Gouttenoire J, Roingeard P, Penin F, **Moradpour D**. Aminoterminal amphipathic α -helix AH2 is a major determinant for the oligomerization of hepatitis C virus nonstructural protein 4B. *J Virol* 2010;84:12529-12537. Featured as a Spotlight in *J Virol* 2010;84:12475.
65. Jirasko V, Montserret R, Lee JY, Gouttenoire J, **Moradpour D**, Penin F, Bartenschlager R. Structural and functional studies of nonstructural protein 2 of the hepatitis C virus reveal its key role as organizer of virion assembly. *PLoS Pathog* 2010;6:e1001233.
66. Popescu C-I, Callens N, Trinel D, Roingeard P, **Moradpour D**, Descamps V, Duverlie G, Penin F, Héliot L, Rouillé Y, Dubuission J. NS2 protein of hepatitis C virus interacts with structural and nonstructural proteins towards virus assembly. *PLoS Pathog* 2011;7:e1001278.
67. Lange CM, **Moradpour D**, Doehring A, Lehr HA, Müllhaupt B, Bibert S, Bochud PY, Antonino AT, Pascual M, Farnik H, Shi Y, Bechstein WO, Moench C, Hansmann ML, Sarrazin C, Lötsch J, Zeuzem S, Hofmann WP. Impact of donor and recipient *IL28B* rs12979860 genotypes on hepatitis C virus liver graft reinfection. *J Hepatol* 2011;55:322-327.
68. Paul D, Romero-Brey I, Gouttenoire J, Stoitsova S, Krijnse-Locker J, **Moradpour D**, Bartenschlager R. NS4B self-interaction through conserved C-terminal elements is

- required for the establishment of functional hepatitis C virus replication complexes. *J Virol* 2011;85:6963-6976.
69. Kenfak Foguena A, Schöni-Affolter F, Bürgisser P, Wittek A, Darling KEA, Kovari H, Kaiser L, Evison J-M, Elzi L, Gurtner-De La Fuente V, Jost J, **Moradpour D**, Abravanel F, Izopet J, Cavassini M, and the Swiss HIV Cohort Study. Hepatitis E virus seroprevalence and chronic infection in HIV-infected patients with unexplained ALT elevation in the Swiss HIV Cohort Study. *Emerg Infect Dis* 2011;17:1074-1078.
 70. Kaufmann A, Kenfak-Foguena A, André C, Canellini G, Bürgisser P, **Moradpour D**, Darling KEA, Cavassini M. Hepatitis E virus seroprevalence among blood donors in Southwest Switzerland. *PLoS One* 2011;6:e21150.
 71. Cai T, Dufour J-F, Müllhaupt B, Gerlach T, Heim M, **Moradpour D**, Cerny A, Malinverni R, Kaddai V, Bochud M, Negro F, Bochud P-Y on behalf of the Swiss Hepatitis C Cohort Study Group. Viral genotype-specific role of *PNPLA3*, *PPARG*, *MTTP* and *IL28B* in hepatitis C virus-associated steatosis. *J Hepatol* 2011;55:529-535.
 72. Wölk B, Trautwein C, Büchele B, Kersting N, Blum HE, Rammensee H-G, Cerny A, Stevanovic S, **Moradpour D***, Brass V*. Identification of naturally processed hepatitis C virus-derived major histocompatibility complex class I ligands. *PLoS One* 2012;7:e29286. *Joint last authors.
 73. Bochud P-Y, Bibert S, Kutalik Z, Patin E, Guergnon J, Nalpas B, Goossens N, Kuske L, Müllhaupt B, Gerlach TJ, Heim MH, **Moradpour D**, Cerny A, Malinverni R, Regenass S, Dollenmaier G, Hirsch H, Martinetti G, Gorgievski M, Bourlière M, Poynard T, Theodorou I, Abel L, Pol S, Dufour J-F, Negro F, on behalf of the Swiss Hepatitis C Cohort Study Group. *IL28B* alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. *Hepatology* 2012;55:384-394.
 74. Lange CM, Kutalik Z, Morikawa K, Bibert S, Cerny A, Dollenmaier G, Dufour J-F, Gerlach TJ, Heim MH, Malinverni R, Müllhaupt B, Negro F, **Moradpour D**, Bochud PY, and the Swiss Hepatitis C Cohort Study Group. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon- α and ribavirin therapy. *Hepatology* 2012;55:1038-1047.
 75. Quarato G, Scrima R, Gavillet B, Vuagniaux G, **Moradpour D**, Capitanio N, Piccoli C. The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction. *Hepatology* 2012;55:1333-1343.
 76. Girardin F, Daali Y, Gex-Fabry M, Rebsamen M, Roux-Lombard P, Cerny A, Bihl F, Binek J, **Moradpour D**, Negro F, Desmeules J, and the Swiss Hepatitis C Cohort Study Group. Liver kidney microsomal type 1 antibodies reduce CYP2D6 activity in patients with chronic hepatitis C virus infection. *J Viral Hepat* 2012;19:568-573.
 77. Lange CM, Bibert S, Kutalik Z, Bürgisser P, Cerny A, Dufour JF, Geier A, Gerlach TJ, Heim MH, Malinverni R, Negro F, Regenass S, Badenhoop K, Bojunga J, Sarrazin C, Zeuzem S, Müller T, Berg T, Bochud PY, **Moradpour D**, and the Swiss Hepatitis C Cohort Study Group. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon- α -based therapy of chronic hepatitis C. *PLoS One* 2012;7:e40159.
 78. Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P, Boland A, Müllhaupt B, Semela D, Dufour JF, Heim MH, **Moradpour D**, Cerny A, Malinverni R, Hirsch H, Martinetti G, Suppiah V, Stewart G, Booth DR, George J, Casanova JL, Bréchet C, Rice CM, Talal AH, Jacobson IM, Bourlière M, Theodorou I, Poynard T, Negro F, Pol S, Bochud PY, Abel L; Swiss Hepatitis C Cohort Study Group, International Hepatitis C Genetics Consortium;

- French ANRS HC EP 26 Genoscan Study Group. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. *Gastroenterology* 2012;143:1244-1252.
79. Kuske L, Mensen A, Müllhaupt B, Negro F, Semela D, **Moradpour D**, Malé PJ, Heim MH, Malinverni R, Cerny A, Dufour J-F, on behalf of the Swiss Hepatitis C Cohort Study Group. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. *Swiss Med Wkly* 2012;142:w13651.
 80. Esser-Nobis K, Romero-Brey I, Ganten TM, Gouttenoire J, Harak C, Klein R, Schemmer P, Binder M, Schnitzler P, **Moradpour D**, Bartenschlager R, Polyak SJ, Stremmel W, Penin F, Eisenbach C, Lohmann V. Analysis of hepatitis C virus resistance to silibinin *in vitro* and *in vivo* points to a novel mechanism involving nonstructural protein 4B. *Hepatology* 2013;57:953-963.
 81. Schnegg A, Bürgisser P, André C, Kenfak-Foguena A, Canellini G, **Moradpour D**, Abravanel F, Izopet J, Cavassini M, Darling KEA. An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population. *PLoS One* 2013;8:e62980.
 82. Rau M, Stickel F, Russmann S, Manser C, Becker P, Weisskopf M, Schmitt J, Dill MT, Dufour JF, **Moradpour D**, Semela D, Müllhaupt B, Geier A. Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with hepatitis C virus infection. *J Hepatol* 2013;58:669-675.
 83. Lange CM, Miki D, Ochi H, Nischalke H-D, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Müllhaupt B, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, **Moradpour D**, Bochud PY, the Hiroshima Liver Study Group, and the Swiss Hepatitis C Cohort Study Group. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. *PLoS One* 2013;8:e64053.
 84. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, Duong FHT, Gerlach T, Malinverni R, **Moradpour D**, Negro F, Müllhaupt B, Bochud P-Y, and the Swiss Hepatitis C Cohort Study. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. *J Exp Med* 2013;210:1109-1116.
 85. Aouri M, **Moradpour D**, Cavassini M, Mercier, T, Buclin T, Csajka C, Telenti A, Rauch A, Decosterd LA. A multiplex LC MS/MS assay for the simultaneous therapeutic drug monitoring of ribavirin, boceprevir and telaprevir. *Antimicrob Agents Chemother* 2013;57:3147-3158.
 86. Lange CM, Bibert S, Dufour JF, Cellerai C, Cerny A, Heim MH, Kaiser L, Malinverni R, Müllhaupt B, Negro F, Semela D, **Moradpour D**, Kutalik Z, Bochud PY, and the Swiss Hepatitis C Cohort Study Group. Comparative genetic analyses point to *HCP5* as susceptibility locus for HCV-associated hepatocellular carcinoma. *J Hepatol* 2013;59:504-509.
 87. Morikawa K, Gouttenoire J, Hernandez C, Dao Thi VL, Tran HTL, Lange CM, Dill MT, Heim MH, Donzé O, Penin F, Quadroni M, **Moradpour D**. Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease. *Hepatology* 2014;59:423-433.
 88. Frei P, Leucht A-K, Held U, Kofmehl R, Schmitt J, Mertens J, Rau M, Baur K, Gerlach TJ, Negro F, Heim MH, **Moradpour D**, Cerny A, Dufour J-F, Müllhaupt B, Geier A, and the Swiss Hepatitis C Cohort Study Group. Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon- α and ribavirin in patients with chronic hepatitis C. *Liver Int* 2014;34:551-557.

89. Lange CM, Bellecave P, Dao Thi VL, Tran HTL, Penin F, **Moradpour D***, Gouttenoire J*. Determinants for membrane association of the hepatitis C virus NS2 protease domain. *J Virol* 2014;88:6519-6523. *Joint corresponding authors.
90. Quarato G, Scrima R, Ripoli M, Agriesti F, **Moradpour D**, Capitanio N, Piccoli C. Protective role of amantadine in mitochondrial dysfunction and oxidative stress mediated by hepatitis C virus protein expression. *Biochem Pharmacol* 2014;89:545-556.
91. Boukadida C, Marnata C, Montserret R, Cohen L, Blumen B, Gouttenoire J, **Moradpour D**, Penin F, Martin A. NS2 proteins of GB virus B and hepatitis C virus share common protease activities and membrane topologies. *J Virol* 2014;88:7426-7444.
92. Lange CM, Gouttenoire J, Duong FHT, Morikawa K, Heim MH, **Moradpour D**. Vitamin D receptor and Jak-STAT signaling crosstalk results in calcitriol-mediated increase of hepatocellular response to interferon- α . *J Immunol* 2014;192:6037-6044.
93. Hoggart CJ, Venturini G, Mangino M, Gomez F, Ascari G, Zhao JH, Teumer A, Winkler TW, Tšernikova N, Luan J, Mihailov E, Ehret GB, Zhang W, Lamparter D, Esko T, Macé A, Rüeger S, Bochud PY, Barcella M, Dauvilliers Y, Benyamin B, Evans DM, Hayward C, Lopez MF, Franke L, Russo A, Heid IM, Salvi E, Vendantam S, Arking DE, Boerwinkle E, Chambers JC, Fiorito G, Grallert H, Guarrera S, Homuth G, Huffman JE, Porteous D; Generation Scotland Consortium; The LifeLines Cohort study; The GIANT Consortium, **Moradpour D**, Iranzo A, Hebebrand J, Kemp JP, Lammers GJ, Aubert V, Heim MH, Martin NG, Montgomery GW, Peraita-Adrados R, Santamaria J, Negro F, Schmidt CO, Scott RA, Spector TD, Strauch K, Völzke H, Wareham NJ, Yuan W, Bell JT, Chakravarti A, Kooner JS, Peters A, Matullo G, Wallaschofski H, Whitfield JB, Paccaud F, Vollenweider P, Bergmann S, Beckmann JS, Tafti M, Hastie ND, Cusi D, Bochud M, Frayling TM, Metspalu A, Jarvelin MR, Scherag A, Smith GD, Borecki IB, Rousson V, Hirschhorn JN, Rivolta C, Loos RJ, Kutalik Z. Novel approach identifies SNPs in SLC2A10 and KCNK9 with evidence for parent-of-origin effect on body mass index. *PLoS Genet* 2014;10:e1004508.
94. Masin M, Vazquez J, Rossi S, Groeneveld SJ, Samson N, Schwalie PC, Deplancke B, Frawley LE, Gouttenoire J, **Moradpour D**, Oliver TG, Meylan E. GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer. *Cancer Metab* 2014;2:11.
95. Morard I, Clément S, Calmy A, Mangia A, Cerny A, De Gottardi A, Gorgievski M, Heim MH, Malinverni R, **Moradpour D**, Müllhaupt B, Semela D, Pascarella S, Bochud P-Y, Negro F, on behalf of the Swiss Hepatitis C Cohort Study Group. Clinical significance of the CCR5 Δ 32 allele in hepatitis C. *PLoS One* 2014;9:e106424.
96. Gouttenoire J, Montserret R, Paul D, Castillo R, Meister S, Bartenschlager R, Penin F, **Moradpour D**. Aminoterminal amphipathic α -helix AH1 of hepatitis C virus nonstructural protein 4B possesses a dual role in RNA replication and virus production. *PLoS Pathog* 2014;10:e1004501.
97. Terczyńska-Dyla E, Bibert S, Duong FHT, Krol I, Jørgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Malinverni R, Mangia A, **Moradpour D**, Müllhaupt B, Negro F, Santoro R, Semela D, Semmo N, Heim MH, Bochud P-Y, Hartmann R. Reduced IFN λ 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. *Nat Commun* 2014;5:5699.
98. Fogeron ML, Badillo A, Jirasko V, Gouttenoire J, Paul D, Lancien L, **Moradpour D**, Bartenschlager R, Meier BH, Penin F, Böckmann A. Wheat germ cell-free expression: two detergents with a low critical micelle concentration allow for production of soluble HCV membrane proteins. *Protein Expr Purif* 2015;105:39-46.

99. Welsch C, Haselow K, Gouttenoire J, Schneider M, Morikawa K, Martinez Y, Susser S, Sarrazin C, Zeuzem S, Antes I, **Moradpour D**, Lange CM. Hepatitis C virus variants resistant to macrocyclic NS3-4A protease inhibitors subvert IFN- β induction by efficient MAVS cleavage. *J Hepatol* 2015;62:779-784.
100. Deltenre P, Trépo E, Rudler M, Monescillo A, Fraga M, Denys A, Doerig C, Fournier N, Moreno C, **Moradpour D**, Bureau C, Thabut D. Early transjugular intrahepatic portosystemic shunt in cirrhotic patients with acute variceal bleeding: a systematic review and meta-analysis of controlled trials. *Eur J Gastroenterol Hepatol* 2015;27:e1-e9.
101. Rüeger S, Bochud P-Y, Dufour J-F, Müllhaupt B, Semela D, Heim MH, **Moradpour D**, Cerny A, Malinverni R, Booth DR, Suppiah V, George J, Argiro L, Halfon P, Bourlière M, Talal AH, Jacobson IM, Patin E, Nalpas B, Poynard T, Pol S, Abel L, Kutalik Z, Negro F. Impact of common risk factors of fibrosis progression in chronic hepatitis C. *Gut* 2015;64:1605-1615.
102. Marot A, Trépo E, Doerig C, Moreno C, **Moradpour D**, Deltenre P. Self-expanding metal stents in patients with cirrhosis and severe or refractory esophageal variceal bleeding: a systematic review and meta-analysis. *Aliment Pharmacol Ther* 2015;42:1250-1260.
103. Dao Thi VL, Debing Y, Wu X, Rice CM, Neyts J, **Moradpour D***, Gouttenoire J*. Sofosbuvir inhibits hepatitis E virus replication *in vitro* and results in an additive effect when combined with ribavirin. *Gastroenterology* 2016;150:82-85. *Joint last and corresponding authors.
104. Winter A, Letang E, Kalinjuma AV, Kimera N, Ntamatungiro A, Glass T, **Moradpour D**, Sahli R, Le Gal F, Furrer H, Wandeler G, and the KIULARCO Study Group. Absence of hepatitis delta infection in a large rural HIV cohort in Tanzania. *Int J Infect Dis* 2016;46:8-10.
105. Bertisch B, Giudici F, Negro F, **Moradpour D**, Müllhaupt B, Moriggia A, Estill J, Keiser O for the Swiss Hepatitis C Cohort Study. Characteristics of foreign-born persons in the Swiss Hepatitis C Cohort Study: implications for screening recommendations. *PLoS One* 2016;11:e0155464.
106. Giudici F, Bertisch B, Negro F, Stirnimann G, Müllhaupt B, **Moradpour D**, Cerny A, Keiser O for the Swiss Hepatitis C Cohort Study. Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centered approach. *J Viral Hepat* 2016;23:697-707.
107. Fogeron M-L, Jirasko V, Penzel S, Paul D, Montserret R, Danis C, Lacabanne D, Badillo A, Gouttenoire J, **Moradpour D**, Bartenschlager R, Penin F, Meier BH, Böckmann A. Cell-free expression, purification, and membrane reconstitution for NMR studies of the nonstructural protein 4B from hepatitis C virus. *J Biomol NMR* 2016;65:87-98.
108. Fraga M, Fournier N, Safroneeva E, Pittet V, Godat S, Straumann A, Nydegger A, Vavricka S, **Moradpour D**, Schoepfer AM, on behalf of the Swiss IBD Cohort Study Group. Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort: prevalence, risk factors, and long-term follow-up. *Eur J Gastroenterol Hepatol* 2017;29:91-97.
109. Ambregna S, Koch S, Sulz MC, Grüner B, Öztürk S, Chevaux J-B, Sulima M, de Gottardi A, Napoléon B, Abergel A, Bichard P, Boytchev I, Deprez P, Dumortier J, Frossard J-L, Kull E, Meny B, **Moradpour D**, Prat F, Vanbiervliet G, Thevenot T, Vuitton DA, Bresson-Hadni S, Vuitton L. A European survey of perendoscopic treatment of biliary complications in patients with alveolar echinococcosis. *Expert Rev*

Anti Infect Ther 2017;15:79-88.

110. Béguelin C, **Moradpour D**, Sahli R, Suter-Riniker F, Lüthi A, Cavassini M, Günthard HF, Battegay M, Bernasconi E, Schmid P, Calmy A, Braun D, Furrer H, Rauch A, Wandeler G and the Swiss HIV Cohort Study. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. *J Hepatol* 2017;66:297-303.
111. Béguelin C, Friolet N, **Moradpour D**, Sahli R, Suter-Riniker F, Lüthi A, Cavassini M, Günthard HF, Battegay M, Bernasconi E, Schmid P, Calmy A, Atkinson A, Rauch A, Wandeler G, and the Swiss HIV Cohort Study. Impact of tenofovir on hepatitis delta virus replication in the Swiss HIV Cohort Study. *Clin Infect Dis* 2017;64:1275-1278.
112. Lenggenhager D, Gouttenoire J, Malehmir M, Bawohl M, Honcharova-Biletska H, Kreutzer S, Semela D, Neuweiler J, Hürlimann S, Aepli P, Fraga M, Sahli R, Terracciano L, Rubbia-Brandt L, Müllhaupt B, Sempoux C, **Moradpour D**, Weber A. Visualization of hepatitis E virus RNA and proteins in the human liver. *J Hepatol* 2017;67:471-479.
113. van Eijk JJJ, Dalton HR, Ripellino P, Madden RG, Jones C, Fritz M, Gobbi C, Melli G, Pasi E, Herrod J, Lissmann RF, Ashraf HH, Abdelrahim M, Al Masri OAB, Fraga M, Benninger D, Kuntzer T, Aubert V, Sahli R, **Moradpour D**, Blasco-Perrin H, Attarian S, Gérolami R, Colson P, Giordani MT, Hartl J, Pischke S, Lin NX, Mclean BN, Bendall RP, Panning M, Peron J-M, Kamar N, Izopet J, Jacobs BC, van Alfen N, van Engelen BGM. Clinical phenotype and outcome of hepatitis E virus associated neuralgic amyotrophy. *Neurology* 2017;89:909-917.
114. Oussalah A, Avogbe PH, Guyot E, Chery C, Guéant-Rodriguez R-M, Ganne-Carrié N, Cobat A, **Moradpour D**, Nalpas B, Negro F, Poynard T, Pol S, Bochud PY, Abel L, Jeulin H, Schvoerer E, Chabi N, Amouzou E, Sanni A, Barraud H, Rouyer P, Josse T, Goffinet L, Jouve JL, Minello A, Bonithon-Kopp C, Thieffin G, Di Martino V, Doffoël M, Richou C, Raab JJ, Hillon P, Bronowicki JP, Guéant JL, the CiRCE Study Group. *BRIP1* coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease. *Oncotarget* 2017;8:62842-62857.
115. Gauthiez E, Habfast-Robertson I, Rüeger S, Kutalik Z, Aubert V, Berg T, Cerny A, Gorgievski M, George J, Heim MH, Malinverni R, **Moradpour D**, Müllhaupt B, Negro F, Semela D, Semmo N, Villard J, Bibert S, Bochud P-Y and the Swiss Hepatitis C Cohort Study. A systematic review and meta-analysis of HCV clearance. *Liver Int* 2017;37:1431-1445.
116. Farhat R, Ankavay M, Lebsir N, Gouttenoire J, Jackson CL, Wychowski C, **Moradpour D**, Dubuisson J, Rouillé Y, Cocquerel L. Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication. *Cell Microbiol* 2018;20:e12804.
117. Keiser O, Giudici F, Müllhaupt B, Junger C, Dufour J-F, **Moradpour D**, Bruggmann P, Terziroli B, Brezzi M, Bertisch B, Estill J, Negro F, Spörri A, and the Swiss Hepatitis C Cohort Study. Trends in hepatitis C-related mortality in Switzerland. *J Viral Hepat* 2018;25:152-160.
118. Wu X, Dao Thi VL, Liu P, Takacs CN, Xiang K, Andrus L, Gouttenoire J, **Moradpour D**, Rice CM. Pan-genotype hepatitis E virus replication in stem cell-derived hepatocellular systems. *Gastroenterology* 2018;154:663-674.
119. Fraga M, Doerig C, Moulin H, Bihl F, Brunner F, Müllhaupt B, Ripellino P, Semela D, Stickel F, Terziroli Beretta-Piccoli B, Aubert F, Telenti A, Greub G, Sahli R and **Moradpour D**. Hepatitis E virus as a cause of acute hepatitis acquired in Switzerland. *Liver Int* 2018;38:619-626.

120. Goossens N, de Vito C, Mangia A, Clément S, Cenderello G, Barrera F, Lampertico P, Coppola N, Zampino R, Stanzione M, Adinolfi LE, Wedemeyer H, Semmo N, Müllhaupt B, Semela D, Malinverni R, **Moradpour D**, Heim M, Trincucci G, Rubbia-Brandt L, Negro F, on behalf of the BOSTIC Study Group. Effect of hepatitis B virus on steatosis in hepatitis C virus coinfecting subjects: a multicenter study and systematic review. *J Viral Hepat* 2018;25:920-929.
121. Saleh M, Welsch C, Cai C, Doehring C, Gouttenoire J, Friedrich J, Haselow K, Sarrazin C, Badenhop K, **Moradpour D**, Zeuzem S, Rueschenbaum S, Lange CM. Differential modulation of hepatitis C virus replication and innate immune pathways by synthetic calcitriol analogs. *J Steroid Biochem Mol Biol* 2018;183:142-151.
122. Gouttenoire J, Pollán A, Abrami L, Oechslin N, Mauron J, Matter M, Oppliger J, Szkolnicka D, Dao Thi VL, van der Goot G, **Moradpour D**. Palmitoylation mediates membrane association of hepatitis E virus ORF3 protein and is required for infectious particle secretion. *PLoS Pathog* 2018;14:e1007471.
123. Saleh M, Rueschenbaum S, Welsch C, Zeuzem S, **Moradpour D**, Gouttenoire J, Lange CM. Glycogen synthase kinase 3 β enhances hepatitis C virus replication by supporting miR-122. *Front Microbiol* 2018;9:2949.
124. Vieira Barbosa J, Fraga M, Saldarriaga J, Hiroz P, Giostra E, Sempoux C, Ferenci P, **Moradpour D**. Hepatic manifestations of Wilson disease: 12-year experience in a Swiss tertiary referral center. *Swiss Med Wkly* 2018;148:w14699.
125. Asgari S, Chaturvedi N, Scepanovic P, Hammer C, Semmo N, Giostra E, Müllhaupt B, Angus P, Thompson AJ, **Moradpour D**, Fellay J. Human genomics of acute liver failure due to hepatitis B virus infection: An exome sequencing study in liver transplant recipients. *J Viral Hepat* 2019;26:271-277.
126. Brezzi M, Bertisch B, Roelens M, **Moradpour D**, Terziroli Beretta-Piccoli B, Semmo N, Müllhaupt B, Semela D, Negro F, Keiser O and the Swiss Hepatitis C Cohort Study. Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study. *PLoS One* 2019;14:e0218706.
127. Terziroli Beretta-Piccoli B, Di Bartolomeo C, Deleonardi G, Grondona AG, Silvestri T, Tesei C, Melidona L, Cerny A, Mertens J, Semmo N, Semela D, **Moradpour D**, Mieli-Vergani G, Vergani D, Muratori L, and the Swiss Hepatitis C Cohort Study. Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents. *J Autoimmun* 2019;102:89-95.
128. Szkolnicka D, Pollán A, Oechslin N, Gouttenoire J, **Moradpour D**. Recombinant hepatitis E viruses harboring tags in the ORF1 protein. *J Virol* 2019;93:e00459-19.
129. Ripellino P, Pasi E, Melli G, Staedler C, Fraga M, **Moradpour D**, Sahli R, Aubert V, Martinetti G, Bihl F, Bernasconi E, Terziroli Beretta-Piccoli B, Cerny A, Dalton HR, Zehnder C, Mathis B, Zecca C, Disanto G, Kaelin-Lang A, Gobbi C. Neurological complications of acute hepatitis E virus infection. *Neurol Neuroimmunol Neuroinflamm* 2020;7:e643.
130. Bertisch B, Brezzi M, Negro F, Müllhaupt B, Ottiger C, Künzler-Heule P, Schmid P, Giudici F, Clerc O, Moriggia A, Roelens M, Marinucci F, Zehnder C, **Moradpour D**, Keiser O; Swiss Hepatitis C Cohort Study. Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing? *Clin Infect Dis* 2020;70:653-659.
131. Tran HTL, Morikawa K, Anggakusuma, Zibi R, Dao Thi VL, Penin F, Heim MH, Quadroni M, Pietschmann T, Gouttenoire J, **Moradpour D**. OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease. *PLoS One*

2020;15:e0236447.

132. Dietz J, Kalinina O, Vermehren J, Peiffer K-H, Matschenz K, Buggisch P, Niederau C, Schattenberg J, Müllhaupt B, Yerly S, Ringelhan M, Schmid R, Antoni C, Mueller T, Schulze zur Wiesch J, Piecha F, **Moradpour D**, Deterding K, Wedemeyer H, Moreno C, Berg T, Berg C, Zeuzem S, Welsch C, Sarrazin C, for the European HCV Resistance Study Group. Resistance-associated substitutions in patients with hepatitis C virus genotype 4 infection. *J Viral Hepat* 2020;27:974-986.
133. Zermatten MG, Fraga M, Bertaggia Calderara D, Aliotta A, **Moradpour D**, Alberio A. Liver dysfunction biomarkers correlate with a prothrombotic and not with a prohemorrhagic profile in cirrhotic patients. *JHEP Rep* 2020;2:100120.
134. Roelens M, Bertisch B, **Moradpour D**, Cerny A, Semmo N, Schmidt P, Müllhaupt B, Junker C, Negro F, Keiser O, for the Swiss Hepatitis C Cohort Study. All-cause mortality and causes of death in the Swiss Hepatitis C Cohort Study. *Open Forum Infect Dis* 2020;7:ofaa308.
135. Lenggenhager D, Pawel S, Honcharova-Biletska H, Evert K, Wenzel JJ, Montani M, Furrer E, Fraga M, **Moradpour D**, Sempoux C, Weber A. The histologic presentation of hepatitis E reflects patients' immune status and preexisting liver condition. *Mod Pathol* 2021;34:233-248.
136. Vieira Barbosa J, Sahli R, Aubert V, Chaouch A, **Moradpour D**, Fraga M. Demographics and outcomes of hepatitis B and D: a 10-year retrospective analysis in a Swiss tertiary referral center. *PLoS One* 2021;16:e0250347.
137. Vieira Barbosa J, Müllhaupt B, Brunner F, Filipowicz Sinnreich M, Semela D, Montani M, Cathomas G, Neuweiler J, Gouttenoire J, Artru F, Louvet A, Mathurin P, Sempoux C, Lenggenhager D, Weber A, **Moradpour D**, Fraga M. Autochthonous hepatitis E as a cause of acute-on-chronic liver failure and death: histopathology can be misleading but transaminases may provide a clue. *Swiss Med Wkly* 2021;151:w20502.
138. Oechslin N, Da Silva N, Szkolnicka D, Hanouille X, **Moradpour D***, Gouttenoire J*. Hepatitis E virus RNA-dependent RNA polymerase is involved in RNA replication and infectious particle production. *Hepatology*, in press (epub Aug 23, 2021 | PMID 34387882). *Corresponding authors.
139. Herderschee J, Heinonen T, Fenwick C, Schrijver IT, Ohmiti K, **Moradpour D**, Cavassini M, Pantaleo G, Roger T, Calandra T, and the Swiss HIV Cohort Study. High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus. *Clin Microbiol Infect*, in press (epub Aug 30, 2021 | PMID 34474121).

Case reports and Letters

1. **Moradpour D**, Flepp M, Frei E, Greminger P. Painful knee, fever [Clinical conference]. *Schweiz Rundsch Med Prax* 1987;76:1207-1210.
2. Ciernik IF, Steiner A, **Moradpour D**, Greminger P, Rhyner K. Nosebleed, visual disorders [Clinical conference]. *Schweiz Rundsch Med Prax* 1990;79:20-22.
3. **Moradpour D**, Markwalder K, Greminger P, Lüthy R. Visceral leishmaniasis as an opportunistic infection. *Schweiz Rundsch Med Prax* 1990;79:921-926.
4. Grüne S, Müllhaupt B, **Moradpour D**, Münch R, Siegenthaler-Zuber G, Siegenthaler W. Primary sclerosing cholangitis. *Dtsch Med Wschr* 1991;116:1095-1100.

5. Simon A, **Moradpour D**, Greminger P. Maculopapular rash, pruritus, upper abdominal pain, attacks of dizziness [Clinical conference]. *Schweiz Rundsch Med Prax* 1991;80:1357-1361.
6. Holch A, Opravil M, **Moradpour D**, Siegenthaler W, Schneider J, Lüthy R. Disseminated toxoplasmosis in AIDS. *Dtsch Med Wschr* 1993;118:814-819.
7. **Moradpour D**, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. *Hepatology* 1994;20:1437-1441.
8. Arnold C, **Moradpour D**, Blum HE. Tuberculous colitis mimicking Crohn's disease. *Am J Gastroenterol* 1998;93:2294-2296.
9. Manuel O, Meylan PR, Rotman S, Fontana M, **Moradpour D**, Pascual M. Oral valganciclovir for cytomegalovirus colitis after liver transplantation [Letter]. *Transplantation* 2007;83:239-240.
10. Fontana M, Ciuffreda D, **Moradpour D**, Pascual M. Combined antiviral therapy for recurrent hepatitis C after liver transplantation [Letter]. *Transplantation* 2007;83:525-526.
11. Fontana M, **Moradpour D**, Aubert V, Estoppey M, Rotman S, Pascual M. Prevalence of anti-HLA antibodies after liver transplantation [Letter]. *Transpl Int* 2010;23:858-859.
12. Niederhauser J, Lobrinus JA, Ochsner F, Wider C, Fellmann F, Yerly P, Antonino AT, Saraiva MJ, **Moradpour D**, Kuntzer T. Successful heart and liver transplantation in a Swiss patient with Glu89Lys transthyretin amyloidosis [Letter]. *Transplantation* 2011;91:e40-e42.
13. Stickel F, Worni M, Pache I, **Moradpour D**, Helbling B, Borovicka J, Kummer O, Gerlach TJ. Optimising ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1 [Letter]. *Am J Gastroenterol* 2013;108:1176-1178.
14. Vionnet J, Pascual M, Chtioui H, Giostra E, Majno PE, Decosterd LA, **Moradpour D**. Sofosbuvir and ribavirin before liver retransplantation for graft failure due to recurrent hepatitis C: a case report. *BMC Gastroenterol* 2015;15:38.
15. Béguelin C, Vazquez M, **Moradpour D**, Sahli R, Suter F, Rauch A, Wandeler G. Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in an HBV/HIV-coinfected patient. *AIDS* 2016;30:530-532.
16. Silva M, Wicki B, Tsouni P, Cunningham S, Doerig C, Zanetti G, Aubert V, Sahli R, **Moradpour D**, Kuntzer T. Hepatitis E virus infection as a direct cause of neuralgic amyotrophy. *Muscle Nerve* 2016;54:325-327.
17. Dao Thi VL, Debing Y, Wu X, Rice CM, Neyts J, **Moradpour D**, Gouttenoire J. Targeting the viral polymerase for treating hepatitis E: How far are we? Reply to the Letter to the Editor by Wang W *et al*. *Gastroenterology* 2016;150:1690-1691.
18. Vionnet J, Saouli AC, Pascual M, Stucker F, Decosterd LA, **Moradpour D**, Chtioui H. Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease. *J Hepatol* 2016;65:1063-1065.
19. Papadakis GE, Lamine F, Chtioui H, Moschouri E, Fraga Christinet M, Marino L, Favre L, Sciarra A, Sempoux C, Schneider A, Duss FR, Sartori C, **Moradpour D**, Sykiotis GP. Rapid remission of Graves' hyperthyroidism without thionamides under immunosuppressive treatment for concomitant autoimmune hepatitis. *Thyroid* 2018;28:276-278.
20. Vionnet J, Yerly P, Aubert JD, Pascual M, Aldenkortt F, Berney T, Giostra E,

- Moradpour D**, Schiffer E. Management of severe portopulmonary hypertension with dual oral therapy prior to liver transplantation. *Transplantation* 2018;102:e194.
21. Vionnet J, Pascual M, Testoni B, Combet C, Godat S, Vijgen S, Aubert V, Rubbia-Brandt L, Zoulim F, **Moradpour D**. Late hepatitis B reactivation following DAA-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient. *Hepatology* 2018;67:791-793.
 22. Sahli R, Fraga M, Semela D, **Moradpour D**, Gouttenoire J. Rabbit HEV in immunosuppressed patients with hepatitis E acquired in Switzerland. *J Hepatol* 2019;70:1023-1025.
 23. Fraga M, Gouttenoire J, Sahli R, Chtioui H, Marcu C, Pascual M, **Moradpour D***, Vionnet J. Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report. *BMC Gastroenterol* 2019;19:76. *Corresponding author.
 24. Moschouri E, Vionnet J, Giostra E, Daccord C, Lazor R, Sciarra A, Letovanec I, Sempoux C, Gonzalez M, Unger S, Fodstad H, Haubitz M, Baerlocher GM, Voruz S, Naveiras O, Jacquemin E, **Moradpour D**, Fraga M. Combined lung and liver transplantation for short telomere syndrome. *Liver Transpl* 2020;26:840-844.
 25. Artru F, Alberio L, **Moradpour D**, Stalder G. Acute immune thrombocytopenia in a patient with decompensated cirrhosis and COVID-19. *BMJ Case Rep* 2020;13:e236815.
 26. Fraga M, **Moradpour D**, Artru F, Romailier E, Tschopp J, Schneider A, Chtioui H, Neerman-Arbez M, Casini A, Alberio L, Sempoux C. Hepatocellular type II fibrinogen inclusions in a patient with severe COVID-19 and hepatitis. *J Hepatol* 2020;73:967-970.
 27. Filippidis P, van Ouwenaller F, Cerutti A, Geiger-Jacquod A, Sempoux C, Pantaleo G, **Moradpour D**, Lamoth F. SARS-CoV-2 as an unexpected causal agent of predominant febrile hepatitis. *F1000Res* 2021;10:400.

Guidelines

1. Sarrazin C, Berg T, Ross RS, Schirmacher P, Wedemeyer H, Neumann U, Schmidt HHJ, Spengler U, Wirth S, Kessler HH, Peck-Radosavljevic M, Ferenci P, Vogel, **Moradpour D**, Heim M, Cornberg M, Protzer U, Manns MP, Fleig WE, Dollinger MM, Zeuzem S. Update der S3-Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus-Infektion [Prophylaxis, diagnosis and therapy of hepatitis C virus infection: The German guidelines on the management of HCV infection]. *Z Gastroenterol* 2010;48:289-351.
2. Swiss Association for the Study of the Liver*. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. *Swiss Med Wkly* 2012;142:w13516. *Corresponding author.
Follow-up Expert Opinion Statements by the Swiss Association for the Study of the Liver and the Swiss Society of Infectious Diseases are published online (cf. other publications below).
3. European Association for the Study of the Liver*. EASL Clinical Practice Guidelines: Wilson's disease. *J Hepatol* 2012;56:671-685. *Member of the guidelines panel.
4. Mallet V, Van Bömmel F, Doerig C, Pischke S, Hermine O, Locasciulli A, Cordonnier C, Berg T, **Moradpour D**, Wedemeyer H, Ljungman P, on behalf of ECIL-5. Management of viral hepatitis in patients with haematological malignancy and in

patients undergoing haematopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). *Lancet Infect Dis* 2016;16:606-617.

5. European Association for the Study of the Liver*. EASL Clinical Practice Guidelines on hepatitis E virus infection. *J Hepatol* 2018;68:1256-1271. *Member of the guidelines panel.
6. Sarrazin C, Zimmermann T, Berg T, Hinrichsen H, Mauss S, Wedemeyer H, Zeuzem S. Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus-Infektion. *Z Gastroenterol* 2020;58:1110-1131. Member of the guidelines panel (collaborator).
7. Bobzin C, Bösiger C, Bruggmann P, Cerny A, Fraga Christinet M, Keiser O, Künzler-Heule P, Lavanchy D, Maeschli B, **Moradpour D**, Negro F, Rauch A, Scheidegger C, Semela D, Semmo N, Thurnheer MC. Empfehlungen für die Nachsorge von Patienten mit ausgeheilter Hepatitis C. *Swiss Med Forum* 2021;21:184-186.

Review articles

1. **Moradpour D**, Wands JR, Melegari M. Chasing the escape mutant. *Hepatology* 1993;18:1011-1014.
2. **Moradpour D** and Wands JR. The molecular pathogenesis of hepatocellular carcinoma. *J Viral Hepat* 1994;1:17-31.
3. **Moradpour D**, Wands JR, Blum HE. Molecular biology of hepatitis B and C virus and hepatocellular carcinoma. *Cancer Mol Biol* 1996;3:875-902.
4. **Moradpour D** und Blum HE. Neue Hepatitisviren: Molekularbiologie und Klinik. *Internist* 1996;37:903-911.
5. **Moradpour D** und Blum HE. Hepatitis C, Diagnostik und Therapie. *Med Klinik* 1996;91:769-770.
6. Blum HE, **Moradpour D**, von Weizsäcker F, Wieland S, Peters T, Rasenack JWS. Hepatitis B Virusmutanten - Klinische Bedeutung. *Z Gastroenterol* 1997;35:347-355.
7. **Moradpour D**, Thimme R, Blum HE. Molekularbiologie in der Inneren Medizin - Bericht über das 24. Ludwig-Heilmeyer-Symposium der Gesellschaft für Fortschritte in der Inneren Medizin. *Dtsch Med Wschr* 1997;122:309-312.
8. von Weizsäcker F, Wieland S, Köck J, Offensperger W-B, Offensperger S, **Moradpour D**, Blum HE. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides and dominant negative mutants. *Hepatology* 1997;26:251-255.
9. Wands JR, Lavaissiere L, **Moradpour D**, de la Monte S, Mohr L, Nicolau C, Tanaka S. Immunological approach to hepatocellular carcinoma. *J Viral Hepat* 1997;4 (Suppl 2): 60-74.
10. **Moradpour D**. Molekulare Krankheitsmodelle: Transgene und Knockout. *Dtsch Med Wschr* 1997;122:1527-1530.
11. **Moradpour D** und Blum HE. Klinische Bedeutung von Hepatitis B Virus Mutanten. *Schweiz Rundsch Med Prax* 1998;87:205-209.
12. **Moradpour D**, Schwacha H, Allgaier H-P, Blum HE. Cholestase: Definition, Differentialdiagnose und laborchemische Diagnostik. *Chir Gastroenterol* 1999;15:7-10.
13. **Moradpour D** und Blum HE. Dolly, Polly et al.: Klonieren durch somatischen Zellkerntransfer. *Dtsch Med Wschr* 1999;124:255-256.

14. **Moradpour D** and Blum HE. Current and evolving therapies for hepatitis C. *Eur J Gastroenterol Hepatol* 1999;11:1199-1202.
15. Offensperger WB, Thoma C, **Moradpour D**, von Weizsäcker F, Offensperger S, Blum HE. Antisense oligonucleotide therapy of hepadnavirus infection. *Methods Enzymol* 1999;314:524-536.
16. Blum HE und **Moradpour D**. Gentechnologische Medikamente und Gentherapie. *Ther Umsch* 1999;56:730-737.
17. **Moradpour D** und Blum HE. DNA Chip-Technologie. *Dtsch Med Wschr* 1999;124:1395-1396.
18. Blum HE und **Moradpour D**. Gentechnologie. *Dtsch Med Wschr* 1999;124:1393-1394.
19. **Moradpour D**, Englert C, Blum HE. Genomics. *Dtsch Med Wschr* 2000;125:529-530.
20. Englert C, **Moradpour D**, Blum HE. Proteomics. *Dtsch Med Wschr* 2000;125:803-804.
21. **Moradpour D** und Blum HE. Molekulare Aspekte des hepatozellulären Karzinoms. *Zentralbl Chir* 2000;125:592-596.
22. **Moradpour D** und Blum HE. DNA-Vakzinierung. *Schweiz Rundsch Med Prax* 2000;89:1745-1748.
23. **Moradpour D**, Cerny A, Heim MH, Blum HE. Hepatitis C: an update. *Swiss Med Wkly* 2001;131:291-298.
24. Blum HE und **Moradpour D**. Diagnostik der chronischen Hepatitis. *Dtsch Med Wschr* 2001;126:783-785.
25. Blum HE und **Moradpour D**. Therapie der chronischen Hepatitis. *Dtsch Med Wschr* 2001;126:786-789.
26. **Moradpour D**, Wölk B, Cerny A, Heim MH, Blum HE. Hepatitis C: a concise review. *Minerva Med* 2001;92:329-339.
27. Wölk B, **Moradpour D**, Blum HE. Neue Nukleinsäure-Nachweisverfahren. *Dtsch Med Wschr* 2001;126:1365-1368.
28. Brass V, Blum HE, **Moradpour D**. Of mice and men: a small animal model of hepatitis C virus replication. *Hepatology* 2002;35:722-724.
29. Gosert R and **Moradpour D**. A new twist to translation initiation of the hepatitis C virus. *Hepatology* 2002;35:724-726.
30. **Moradpour D** und Blum HE. Therapie der Hepatitis C: aktueller Stand und neue Entwicklungen. *Schweiz Rundsch Med Prax* 2002;91:977-982.
31. **Moradpour D**. Of mice and men - ein In-vivo-Modell der Hepatitis-C-Virus-Replikation. *Schweiz Med Forum* 2002;2:638-639.
32. Gosert R and **Moradpour D**. Reading between the lines: evidence for a new hepatitis C virus protein. *Hepatology* 2002;36:757-760.
33. **Moradpour D**, Brass V, Gosert R, Wölk B, Blum HE. Hepatitis C: molecular virology and antiviral targets. *Trends Mol Med* 2002;8:476-482.
34. Dubuisson J, Penin F, **Moradpour D**. Interaction of hepatitis C virus proteins with host cell membranes and lipids. *Trends Cell Biol* 2002;12:517-523.
35. Blum HE and **Moradpour D**. Antiviral treatment of patients with HBV-related cirrhosis. *J Gastroenterol Hepatol* 2002;17 (Suppl 3):S306-S310.
36. Blum HE and **Moradpour D**. Viral pathogenesis of hepatocellular carcinoma. *J Gastroenterol Hepatol* 2002;17 (Suppl 3):S413-S420.

37. **Moradpour D**, Brass V, Gosert R, Wölk B, Blum HE. Molekulare Virologie der Hepatitis C. Schweiz Rundsch Med Prax 2002;91:2247-2253.
38. Castet V and **Moradpour D**. A model for the study of hepatitis C virus entry. Hepatology 2003;38:771-774.
39. **Moradpour D**, Gosert R, Egger D, Penin F, Blum HE, Bienz K. Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. Antiviral Res 2003;60:103-109.
40. Penin F, Dubuisson J, Rey FA, **Moradpour D**, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004;39:5-19.
41. **Moradpour D** und Blum HE. Hepatitis C: Update 2003. Der Mikrobiologe 2004;14:51-56.
42. **Moradpour D**. Hepatology highlights: viral hepatitis. Hepatology 2004;40:4-5.
43. Brass V, Blum HE, **Moradpour D**. Recent developments in target identification against hepatitis C virus. Expert Opin Ther Targets 2004;8:295-307.
44. **Moradpour D** und Blum HE. Hepatitis C. Ther Umsch 2004;61:493-498.
45. Pache I et **Moradpour D**. Transmission et prévention des hépatites virales. Med Hyg 2004;62:1888-1894.
46. **Moradpour D** and Blum HE. A primer on the molecular virology of hepatitis C. Liver Int 2004;24:519-525.
47. **Moradpour D** und Blum HE. Diagnostik der Hepatitis B und C: Update 2004. Schweiz Rundsch Med Prax 2005;94:66-72.
48. Pache I, Hess J, Gonvers JJ, **Moradpour D**. Quand et comment traiter les hépatites B et C ? Rev Med Suisse 2005;1:237-241.
49. Hess J, Thorens J, Pache I, Troillet FX, **Moradpour D**, Gonvers JJ. Les hépatopathies auto-immunes et leurs traitements. Rev Med Suisse 2005;1:242-247.
50. Troillet FX, Halkic N, Froehlich F, **Moradpour D**, Gonvers JJ, Denys A. Les complications de la cirrhose hépatique: varices oesophagiennes, ascite et carcinome hépato-cellulaire. Rev Med Suisse 2005;1:249-255.
51. **Moradpour D** and Blum HE. Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005;17:477-483.
52. Tempia-Caliera AA, Ksontini R, **Moradpour D**, Denys A, Halkic N. Le carcinome hépato-cellulaire: une approche multidisciplinaire. Rev Med Suisse 2005;1:1621-1629.
53. **Moradpour D**, Gonvers JJ, Blum HE. Therapie der chronischen Hepatitis C. Schweiz Med Forum 2005;5:679-685.
54. **Moradpour D**, Brass V, Penin F. Function follows form: the structure of the N-terminal domain of HCV NS5A. Hepatology 2005;42:732-735.
55. Berke JM and **Moradpour D**. Hepatitis C virus comes full circle: production of recombinant infectious virus in tissue culture. Hepatology 2005;42:1264-1269.
56. Mondada D, Pache I, Leopold K, Thorens J, **Moradpour D**, Gonvers JJ. Acquisitions thérapeutiques 2005: Hépatologie. Rev Med Suisse 2006;2:218-230.
57. Brass V, **Moradpour D**, Blum HE. Molecular virology of hepatitis C: 2006 update. Int J Med Sci 2006;3:29-34.
58. **Moradpour D** und Blum HE. Therapie der chronischen Hepatitis C. Schweiz Med Rundsch Prax 2006;95:1451-1457.

59. Bellecave P and **Moradpour D**. A picture says more than a thousand words: structural insights into hepatitis C virus translation initiation. *Hepatology* 2006;44:1687-1690.
60. Gouttenoire J, **Moradpour D**, Penin F. Surprises from the three-dimensional structure of the hepatitis C virus NS2-3 protease. *Hepatology* 2006;44:1690-1693.
61. Pache I, Mondada D, Fontana M, **Moradpour D**. Acquisitions thérapeutiques 2006: prise en charge des hépatites virales chroniques. *Rev Med Suisse* 2007;3:215-223.
62. **Moradpour D**, Penin F, Rice CM. Replication of hepatitis C virus. *Nat Rev Microbiol* 2007;5:453-463.
63. Brass V, **Moradpour D**, Blum HE. Hepatitis C virus infection: *in vivo* and *in vitro* models. *J Viral Hepat* 2007;14 (Suppl 1):64-67.
64. Pache I et **Moradpour D**. Actualités en hépatologie. *Rev Med Suisse* 2008;4:214-220.
65. Fontana M, Giostra E, Pilon N, Michetti P, Mentha G, Pascual M, **Moradpour D**. Transplantation hépatique: introduction en Suisse d'un nouveau système d'allocation des organes. *Rev Med Suisse* 2008;4:221-223.
66. Baid-Agrawal S, Pascual M, **Moradpour D**, Frei U, Tolkoff-Rubin N. Hepatitis C virus infection in hemodialysis and kidney transplant patients. *Rev Med Virol* 2008;18:97-115.
67. Bellecave P and **Moradpour D**. A fresh look at interferon- α signaling and treatment outcomes in chronic hepatitis C. *Hepatology* 2008;48:1330-1333.
68. **Moradpour D**, Pache I, Hohlfeld P. Schwangerschaftsassozierte Lebererkrankungen. *Schweiz Med Forum* 2008;42:790-796.
69. Pache I and **Moradpour D**. Hépatite C chez la personne âgée. *Gériatrie Pratique* 2008;5:15-17.
70. Brass V, Gosert R, **Moradpour D**. Investigation of the hepatitis C virus replication complex. *Methods Mol Biol* 2009;510:195-209.
71. Pache I, Leung Ki E-L, Antonino A, **Moradpour D**. Actualités en hépatologie. *Rev Med Suisse* 2009;5:195-202.
72. Doerig C, Sahli R, Telenti A, **Moradpour D**. Prévention et prise en charge de la résistance antivirale dans l'hépatite B chronique. *Rev Med Suisse* 2009;5:203-208.
73. Leung Ki E-L, Pache I, **Moradpour D**. Hepatitis D. *Schweiz Med Forum* 2009;9:184-187.
74. Capitanio N, **Moradpour D**, Piccoli C. HCV proteins alter mitochondrial calcium and redox homeostasis: Insights into pathogenesis of hepatitis C. *Drug Discovery Today: Disease Mechanisms* 2009;6:e3-e10.
75. Doerig C, Antonino A, Pache I, **Moradpour D**. Prise en charge de l'hépatite B chronique: un défi en évolution constante. *Rev Med Suisse* 2010;6:168-173.
76. Bihl F, Pache I, Hess J, **Moradpour D**. Le point sur le traitement de l'hépatite C chronique. *Rev Med Suisse* 2010;6:174-179.
77. Pache I, Bize P, Halkic N, Montemurro M, Giostra E, Majno P, **Moradpour D**. Prise en charge du carcinome hépatocellulaire en 2010. *Rev Med Suisse* 2010;6:198-202.
78. Gouttenoire J, Penin F, **Moradpour D**. Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory. *Rev Med Virol* 2010;20:117-129.
79. **Moradpour D** and Negro F. Hépatite D - oubliée mais pas disparue. *Rev Med Suisse* 2010;6:1656-1659.

80. Schoepfer A, Pache I, Nichita C, Dorta G, **Moradpour D**. Actualités en gastro-entérologie et hépatologie. Rev Med Suisse 2011;7:25-29.
81. Mentha G, Majno P, Morard I, Toso C, Moldovan B, Antonino A, Berney T, Morel P, Rubbia-Brandt L, Terraz S, **Moradpour D**, Hadengue A, Giostra E. La transplantation hépatique. Rev Med Suisse 2011;7:192-193.
82. **Moradpour D** and Blum HE. Virushepatitis. Ther Umsch 2011;68:175-181.
83. Morikawa K, Lange CM, Gouttenoire J, Brass V, Penin F, **Moradpour D**. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J Viral Hepat 2011;18:305-315.
84. Godat S, **Moradpour D**, Schoepfer A. Oesophagite à éosinophiles : mise à jour 2011. Rev Med Suisse 2011;7:1678-1682.
85. Hiroz P, Antonino A, Doerig C, Pache I, **Moradpour D**. La maladie de Wilson : un caméléon clinique auquel il faut penser. Rev Med Suisse 2011;7:1690-1695.
86. Manuel O, Baid-Agrawal S, **Moradpour D**, Pascual M. Immunosuppression in hepatitis C virus-infected patients after kidney transplantation. Contrib Nephrol 2012;176:97-107.
87. Gencer B, **Moradpour D**, Rodondi N. Traitement des dyslipidémies et atteinte hépatique. Rev Med Suisse 2012;8:507-512.
88. Godat S, Antonino AT, Dehlavi M-A, **Moradpour D**, Doerig C. Hypertension portale et prise en charge de l'ascite. Rev Med Suisse 2012;8:1665-1668.
89. Fraga M, Godat S, Nydegger A, **Moradpour D**, Schoepfer AM. Calprotective fécale : Outil diagnostique dans les maladies inflammatoires chroniques de l'intestin. Rev Med Suisse 2012;8:1669-1673.
90. Schneider MP, Genre N, Reymermier M, Bugnon O, **Moradpour D**. Hépatite C - Avancées thérapeutiques. pharmaJournal 11.2012, No 24, pp. 5-9.
91. Quarato G, Scrima R, Agriesti F, **Moradpour D**, Capitanio N, Piccoli C. Targeting mitochondria in the infection strategy of the hepatitis C virus. Int J Biochem Cell Biol 2013;45:156-166.
92. Müllhaupt B and **Moradpour D**. Schlaglicht Hepatologie: Wichtiges zur chronischen Hepatitis C. Schweiz Med Forum 2013;13:28-30.
93. **Moradpour D** and Penin F. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol 2013;369:113-142.
94. Hiroz P, Gouttenoire J, Dao Thi VL, Sahli R, Telenti A, **Moradpour D**, Doerig C. Mise à jour sur l'hépatite E. Rev Med Suisse 2013;9:1594-1598.
95. Thimme R, Heim M, Baumert T, Nassal M, **Moradpour D**. Hepatitis B und C: von der molekularen Virologie zu neuen Perspektiven in der Therapie. Herrn Prof. Dr. Dr. h.c. mult. H.E. Blum zum 70. Geburtstag. Dtsch Med Wochenschr 2014;139:655-659 (part 1) and 778-782 (part 2).
96. Boettler T, **Moradpour D**, Thimme R, Zoulim F. Bridging Basic Science and Clinical Research - The EASL Monothematic Conference on Translational Research in Viral Hepatitis. J Hepatol 2014;61:696-705.
97. Deltenre P and **Moradpour D**. Actualités diagnostiques et thérapeutiques dans le domaine de l'encéphalopathie hépatique. Rev Med Suisse 2014;10:1600-1606.
98. Chtioui H, Buclin T and **Moradpour D**. Nouveaux traitements de l'hépatite C : aspects pharmacologiques et potential d'interaction. Rev Med Suisse 2014;10:1612-1616.

99. Baid-Agrawal S, Pascual M, **Moradpour D**, Somasundaram R, Muche M. Hepatitis C virus infection and kidney transplantation in 2014: what's new? *Am J Transpl* 2014;2206-2220.
100. Burgmann K and **Moradpour D**. Hepatitis C - ein Update. *Der informierte Arzt* 2014;4:17-19.
101. **Moradpour D** und Müllhaupt B. Hepatitis C: Epidemiologie, natürlicher Verlauf und Diagnostik. *Swiss Med Forum* 2015;15:360-365.
[French version: Hépatite C : épidémiologie, histoire naturelle et diagnostic. *Rev Med Suisse* 2015;11:896-901.]
102. **Moradpour D** und Müllhaupt B. Hepatitis C: aktuelle Therapie. *Swiss Med Forum* 2015;15:366-370.
[French version: Hépatite C : traitement actuel. *Rev Med Suisse* 2015;11:902-906.]
103. Müllhaupt B und **Moradpour D**. Hepatitis C: Information für Patienten. *Swiss Med Forum* 2015;15:371-372.
[French version: Hépatite C : information pour les patients. *Rev Med Suisse* 2015;15:907-908.]
104. Debing Y, **Moradpour D**, Neyts J, Gouttenoire J. Update on hepatitis E virology: implications for clinical practice. *J Hepatol* 2016;65:200-212.
105. Béguelin C, Fraga M, Wandeler G, Sahli R, Rauch A, **Moradpour D**. Hepatitis E. *Swiss Med Forum* 2016;16:510-514
[French version: *Forum Méd Suisse* 2016;16:510-514].
106. Burgmann K, Brunel C, Sempoux C, Ribl C, Godat S, **Moradpour D**, Schoepfer AM. Gastro-entérite à éosinophiles. *Rev Med Suisse* 2016;12:1419-1423.
107. Vionnet J, Pascual M, Kuntzer T, Yerly P, **Moradpour D**. Amyloïdose héréditaire à transthyréline. *Rev Med Suisse* 2016;12:1434-1440.
108. **Moradpour D**, Grakoui A, Manns MP. Future landscape of hepatitis C research - basic, translational and clinical perspectives. *J Hepatol* 2016;65 Suppl 1:S143-S155.
109. Fraga M, Gouttenoire J, Sahli R, **Moradpour D**. Akute und chronische Hepatitis E. *Ther Umsch* 2017;74:109-113.
110. Allgaier H-P, Arnold C, Baumert TF, Becker G, Geissler M, Hafkemeyer P, Harder J, Heim MH, Huber R, Kern WV, Mohr L, **Moradpour D**, Offensperger S, Offensperger W-B, Spangenberg H-C, Thimme R, Walter E, von Weizsäcker F. Von der molekularen Medizin bis zur Naturheilkunde: das breite Tätigkeitsfeld von Herrn Prof. Dr. Dr. h.c. mult. Hubert E. Blum. *Dtsch Med Wschr* 2018;143:40-45.
111. Bartenschlager R, Baumert TF, Bukh J, Houghton M, Lemon SM, Lindenbach BD, Lohmann V, **Moradpour D**, Pietschmann T, Rice CM, Thimme R, Wakita T. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: considerations for scientists and funding agencies. *Virus Res* 2018;248:53-62.
112. Scrima R, Piccoli C, **Moradpour D**, Capitanio N. Targeting endoplasmic reticulum and/or mitochondrial Ca²⁺ fluxes as therapeutic strategy for HCV infection. *Front Chem* 2018;6:73.
113. Vieira Barbosa J, Vionnet J, Sciarra A, Sempoux C, Aubert V, **Moradpour D**, Fraga Christinet M. Cholangite biliaire primitive : mise à jour. *Rev Med Suisse* 2018;14:1489-1494.
114. Henchoz S, Fraga M, Saouli A-C, Elkrief L, Berney T, Toso C, Compagnon P, Andres A, Denys A, Pascual M, **Moradpour D**, Giostra E, Vionnet J pour le Centre Universitaire Romand de Transplantation. Suivi ambulatoire du patient transplanté

- hépatique : le role essential du médecin généraliste. Rev Med Suisse 2019;15:1488-1495.
115. Wakim El-Khoury J, Venetz J-P, Rutz T, Sciarra A, Unger S, Sempoux C, **Moradpour D**, Fraga M. Syndrome d'Alagille. Rev Med Suisse 2019;15:1506-1510.
 116. Gotlieb N, **Moradpour D**, Shouval D. Snapshot: Hepatitis A and E - differences and commonalities. J Hepatol 2020;72:578-580.
 117. Golshayan D, Aubert J-D, Hullin R, **Moradpour D**, Venetz J-P, Manuel O, Pascual M. Infection à SARS-CoV-2 et transplantation d'organes solides. Rev Med Suisse 2020;16:815-818.
 118. Zermatten MG, Fraga M, **Moradpour D**, Bertaggia Calderara D, Aliotta A, Stirnimann G, De Gottardi A, Alberio L. Hemostatic alterations in cirrhotic patients: from primary hemostatis to fibrinolysis. Hepatology 2020;71:815-818.
 119. Oechslin N, **Moradpour D**, Gouttenoire J. On the host side of the hepatitis E virus life cycle. Cells 2020;9:E1294.
 120. Romailier E, Schmidt S, **Moradpour D**, Sempoux C. Adénomes hépatocellulaires : update 2020. Rev Med Suisse 2020;16:1554-1559.
 121. Shams T, Moschouri E, Denys A, **Moradpour D**, Fraga M, Artru F. Early TIPS : une revue pratique après 15 ans d'évidence scientifique. Rev Med Suisse 2020;16:1548-1553.
 122. Artru F, Fraga M, Godat S, Schoepfer AM, **Moradpour D**. Nouveautés en médecine 2020 : Gastroentérologie et hépatologie. Rev Med Suisse 2021;17:29-32.
 123. Stamm G-M, Sempoux C, Fraga M, Comte D, Aubert V, **Moradpour D**, Vionnet J, Moschouri E. Hépatite auto-immune : mise au point en 2021. Rev Med Suisse 2021;17:1457-1463.

Editorials

1. **Moradpour D** and Wands JR. Understanding hepatitis B virus infection. N Engl J Med 1995;332:1092-1093.
2. Michetti P et **Moradpour D**. Traitement de l'hépatite B : nouveaux moyens, nouveaux espoirs et nouveaux défis. Rev Med Suisse 2007;3:187-188.
3. Brass V and **Moradpour D**. New insights into hepatitis B and C virus coinfection. J Hepatol 2009;51:423-425.
4. Wölk B and **Moradpour D**. The promise of advanced imaging techniques for the detection of hepatitis C virus antigens in the infected liver. Gastroenterology 2009;137: 1214-1218. Featured as cover illustration.
5. **Moradpour D** et Dorta G. L'hépatite C au carrefour. Rev Med Suisse 2010;6:163-164.
6. **Moradpour D**. Neues aus der Hepatologie. Ther Umsch 2011;68:173-174.
7. **Moradpour D** et Hadengue A. L'ère qui s'ouvre dans la prise en charges des patients atteints d'hépatite C. Rev Med Suisse 2011;7:1667-1668.
8. Hadengue A et **Moradpour D**. La maladie alcoolique du foie : un autre maladie négligée ?. Rev Med Suisse 2012;8:1643-1644.
9. **Moradpour D** et Frossard J-L. Progrès et nouveaux défis dans l'hépatite C. Rev Med Suisse 2013;9:1563-1564.
10. Frossard J-L et **Moradpour D**. Café et pancréas : la demi-vie de la vérité en médecine. Rev Med Suisse 2014;10:1579.

11. **Moradpour D** et Frossard J-L. Hépatite C : 25 ans de progrès avec encore des défis majeurs. *Rev Med Suisse* 2015;11:1579-1580.
12. Gouttenoire J and **Moradpour D**. A mouse model for hepatitis E virus infection. *J Hepatol* 2016;64:1003-1005.
13. Gouttenoire J, Szkolnicka D, **Moradpour D**. Treatment of chronic hepatitis E with ribavirin: lessons from deep sequencing. *Gut* 2016;65:1583-1584.
14. Frossard J-L et **Moradpour D**. Transplantation fécale : les faits et les espoirs démesurés ? *Rev Med Suisse* 2016;12:1403-1404.
15. **Moradpour D** et Frossard J-L. Hépatite E : Qui cherche ... trouve ! *Rev Med Suisse* 2017;13:1451-1452.
16. Negro F et **Moradpour D**. Hépatologie 2018 : un paysage en pleine évolution. *Rev Med Suisse* 2018;14 Suppl:S2-3.
17. Frossard J-L et **Moradpour D**. Clostridium - si difficile et si onéreux. *Rev Med Suisse* 2018;14:1483.
18. Moradpour D et Frossard J-L. L'hépatologie opère sa mue. *Rev Med Suisse* 2019;15:1475-1476.
19. Oechslin N, **Moradpour D**, Gouttenoire J. Hepatitis E virus finds its path through the gut. *Gut* 2020;69:796-798.
20. Negro F et **Moradpour D**. COVID-19 et hépatologie. *Rev Med Suisse* 2020;16:1535-1536.

Book chapters

1. **Moradpour D** and Wands JR. Hepatic oncogenesis. In: *Hepatology. A Textbook of Liver Disease*. Zakim D and Boyer TD, eds. 3rd edition. W.B. Saunders, Philadelphia, 1996, pp. 1490-1512.
2. Blum HE, Wieland S, von Weizsäcker F, Offensperger W-B, Offensperger S, **Moradpour D**, Chemin I, Walter E. Experimental therapies in viral hepatitis. Update on Hepatobiliary Diseases No. 90. Kluwer Academic Publishers, Lancaster, UK, 1996, pp. 43-53.
3. **Moradpour D** and Blum HE. Hepatitis C and G. In: *New Trends in Hepatology 1996 - Proceedings of the Falk Symposium No. 92*, St. Petersburg. Gerok W, Loginov AS, Pokrowskij VI, eds. Kluwer Academic Publishers, Lancaster, UK, 1997, pp. 10-26.
4. Blum HE und **Moradpour D**. Hepatitis C: Neue therapeutische Strategien. In: *Hepatitis C*. Häussinger D und Niederau C, Hrsg. Blackwell Scientific, Berlin, 1997, S. 269-281.
5. Offensperger W-B, von Weizsäcker F, Wieland S, **Moradpour D**, Walter E, Offensperger S, Blum HE. Gentherapeutische Strategien in der Virologie. In: *Molekularbiologie in der Inneren Medizin. Schriftenreihe der Gesellschaft für Fortschritte in der Inneren Medizin*. Blum HE und Siegenthaler W, Hrsg. Georg Thieme Verlag, Stuttgart - New York, 1997, S. 188-194.
6. Blum HE and **Moradpour D**. Treatment of chronic hepatitis B: therapeutic vaccines. In: *Transfusion-associated hepatitis. Diagnosis, treatment and prevention*. Sarin SK and Hess G, eds. CBS Publications, New Delhi, India, 1998, pp. 377-381.
7. Blum HE, Wieland S, Walter E, von Weizsäcker F, Offensperger WB, **Moradpour D**. Natural course of HBV infection. In: *Hepatitis B virus: molecular mechanisms in*

- disease and novel strategies for therapy. Koshy R and Caselmann W, eds. Imperial College Press, 1998, pp. 75-92.
8. Blum HE, **Moradpour D**, Köck J, Tang Z-Y, von Weizsäcker F, Offensperger W-B. Gene therapy for hepatocellular carcinoma: concepts and perspectives. In: Normal and malignant liver cell growth. Fleig W, ed. Kluwer Academic Publishers, Dordrecht - Boston - London, 1998, pp. 232-242.
 9. Offensperger WB, Madon J, Thoma C, **Moradpour D**, von Weizsäcker F, Blum HE. Strategies for targeted delivery of antisense oligonucleotides into hepatocytes. In: Manual of antisense methodology. Endres S and Hartmann G, eds. Kluwer Academic Publishers, Boston - Dordrecht - London, 1999, pp. 57-77.
 10. **Moradpour D**, Ammann R, Blum HE. Schmerzen im Bereich des Abdomens. In: Differentialdiagnose innerer Krankheiten. Siegenthaler W, Hrsg. 18. Auflage. Georg Thieme Verlag, Stuttgart - New York, 1999, S. 215-257.
 11. **Moradpour D**, Ammann R, Blum HE. Ikterus. In: Differentialdiagnose innerer Krankheiten. Siegenthaler W, Hrsg. 18. Auflage. Georg Thieme Verlag, Stuttgart - New York, 1999, S. 697-733.
 12. **Moradpour D**. Biologie des Hepatitis C Virus. In: Chronische Virushepatitis - Aktueller Stand und Perspektiven. Blum HE, Maier KP, Paumgartner G, Upmeyer HJ, Hrsg. Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2000, S. 21-27.
 13. **Moradpour D**, Heim MH, Blum HE. Interferons and viral replication in the liver. In: Andus T and Schölmerich J, eds. Cytokines and cell homeostasis in the gastrointestinal tract. Kluwer Academic Publishers, Dordrecht - Boston - London, 2000, pp. 192-205.
 14. **Moradpour D** and Blum HE. Virology and diagnosis of hepatitis C. In: Boyer J, Blum HE, Maier K-P, Sauerbruch T, Stalder GA, eds. Liver cirrhosis and its development. Kluwer Academic Publishers, Dordrecht - Boston - London, 2000, pp. 98-112.
 15. Blum HE, Baumert T, Geissler M, Hafkemeyer P, Köck J, Linhart HG, Mohr L, **Moradpour D**, Offensperger W-B, Thoma C, von Weizsäcker F. Gene therapy of viral hepatitis and its sequelae. Proceedings of the Falk Workshop in Cologne, January 27-28, 2000. Kluwer Academic Publishers, Dordrecht - Boston - London, 2000, pp. 255-268.
 16. Blum HE, Baumert T, Geissler M, Köck J, **Moradpour D**, Offensperger S, Offensperger W-B, von Weizsäcker F. Viral hepatitis: the molecular approach. In: Gerbes AL, Beuers U, Jüngst D, Pape GR, Sackmann M, Sauerbruch T, eds. Hepatology 2000. Proceedings of the Falk Symposium No. 117. Kluwer Academic Publishers, Dordrecht - Boston - London, 2001, pp. 243-252.
 17. **Moradpour D** und Blum HE. Hepatitis C: Neue therapeutische Konzepte. In: Hepatitis C. Häussinger D und Niederau C, Hrsg. Blackwell Wissenschafts-Verlag, Berlin, 2001, S. 306-323.
 18. **Moradpour D**, Allgaier HP, Linhart HG, Blum HE. Hepatozelluläres Karzinom. In: Molekularmedizinische Grundlagen von nicht-hereditären Tumorerkrankungen. Ganten D und Ruckpaul K, Hrsg. Springer Verlag, Berlin, 2002, S. 207-229.
 19. **Moradpour D** und Blum HE. Epidemiologie und Klinik des hepatozellulären Karzinoms. In: Das hepatozelluläre Karzinom. Allgaier H-P, Hrsg. UNI-MED Science, Bremen, 2002, S. 13-16.
 20. **Moradpour D** und Blum HE. Pathogenese des hepatozellulären Karzinoms. In: Das hepatozelluläre Karzinom. Allgaier H-P, Hrsg. UNI-MED Science, Bremen, 2002, S. 17-26.

21. Bauer TM, **Moradpour D**, Blum HE. Folgen des Alkohols. In: Der klinisch-infektiologische Fall. Problemorientierte Diagnose und Therapie. Geiss HK, Jacobs E, Mack D, Hrsg. Springer-Verlag, Berlin - Heidelberg - New York, 2002, S. 14-18.
22. **Moradpour D**, Frese M, Heim MH, Haller O, Bartenschlager R, Blum HE. Cytokine-mediated control of hepatitis C virus replication. In: Immunology and the liver: cytokines. Moreno-Otero R, Albillos A, García-Monzón C, eds. Acción Médica, Madrid - Barcelona - Sevilla, 2002, pp. 297-302.
23. **Moradpour D**, Frese M, Heim MH, Haller O, Bartenschlager R, Blum HE. Cytokines and hepatitis C virus replication. In: Cytokines in liver injury and repair. Gressner AM, Heinrich PC, Matern A, eds. Kluwer Academic Publishers, Dordrecht - Boston - London, 2002, pp. 105-120.
24. **Moradpour D** and Wands JR. Molecular pathogenesis of hepatocellular carcinoma. In: Hepatology. A Textbook of Liver Disease. Zakim D and Boyer TD, eds. 4th edition. W.B. Saunders, Philadelphia, 2002, pp. 1333-1354.
25. **Moradpour D** and Blum HE. Hepatitis B carrier: definition and diagnosis. In: Sarin SK and Okuda K, eds. Hepatitis B and C: carrier to cancer. Harcourt / Elsevier Science, New Delhi, India, 2002, pp. 3-8.
26. Blum HE and **Moradpour D**. Chronic hepatitis B: current therapeutic options. In: Sarin SK and Okuda K, eds. Hepatitis B and C: carrier to cancer. Harcourt / Elsevier Science, New Delhi, India, 2002, pp. 129-133.
27. **Moradpour D** and Blum HE. Molecular pathogenesis of hepatocellular carcinoma. In: Sarin SK and Okuda K, eds. Hepatitis B and C: carrier to cancer. Harcourt / Elsevier Science, New Delhi, India, 2002, pp. 289-299.
28. **Moradpour D**, Heim MH, Cerny A, Rice CM, Blum HE. Cell lines that allow regulated expression of HCV proteins: principles and applications. In: Frontiers in Viral Hepatitis. Schinazi RF, Sommadossi J-P, Rice CM, eds. Elsevier B.V., Amsterdam, The Netherlands, 2003, pp. 175-186.
29. **Moradpour D** and Blum HE. Treatment of hepatitis B in special patient groups. In: Blum HE, Maier K-P, Rodés J, Sauerbruch T, eds. Liver diseases: advances in treatment and prevention. Lancaster Publishing Services, Lancaster, UK, 2004, pp. 133-141.
30. **Moradpour D**, Offensperger WB, von Weizsäcker F, Blum HE. Gene therapy for hepatitis B. In: Sarin SK and Singal AK, eds. Hepatitis B in India - Prevention and Management. CBS Publishers & Distributors, New Delhi - Bangalore, India, 2004, pp. 530-538.
31. Rice CM, You S, Randall G, Zhang J, McMullan LK, Marcello T, Grakoui A, Hanson HL, **Moradpour D**, Lindenbach BD, and McKeating JA. Hepatitis C: unraveling the details of hepatitis C virus replication and immunity. In: Viral hepatitis and liver disease. Jilbert AR, Grgacic EVL, Vickery K, Burrell CJ, Cossart YE, eds. Australian Centre for Hepatitis Virology, Sydney, Australia, 2004, pp. 32-38.
32. **Moradpour D** und Blum HE. Schmerzen im Bereich des Abdomens. In: Differenzialdiagnose innerer Krankheiten. Siegenthaler W, Hrsg. 19. Auflage. Georg Thieme Verlag, Stuttgart - New York, 2005, S. 258-301.
33. **Moradpour D** und Blum HE. Ikterus. In: Differenzialdiagnose innerer Krankheiten. Siegenthaler W, Hrsg. 19. Auflage. Georg Thieme Verlag, Stuttgart - New York, 2005, S. 770-809.
34. **Moradpour D**, Heim MH, Blum HE. Mechanisms of interferon resistance. In: Viral hepatitis. Thomas HC, Zuckermann AJ, Lemon SM, eds. 3rd edition. Blackwell Publishing Ltd, Oxford, UK, 2005, pp. 815-823.

35. **Moradpour D.** Leber. In: Klinische Pathophysiologie. Siegenthaler W und Blum HE, Hrsg. 9. Auflage, Georg Thieme Verlag, Stuttgart - New York, 2006, pp. 859-888.
36. **Moradpour D** and Rice CM. Replication and pathogenesis of hepatitis C virus. In: Zakim & Boyer's Hepatology. A Textbook of Liver Disease. Boyer TD, Manns MP, Wright TL, eds. 5th edition. Elsevier Science, Philadelphia, PA, 2006, pp. 125-147.
37. Wands JR and **Moradpour D.** Molecular pathogenesis of hepatocellular carcinoma. In: Zakim & Boyer's Hepatology. A Textbook of Liver Disease. Boyer TD, Manns MP, Wright TL, eds. 5th edition. Elsevier Science, Philadelphia, PA, 2006, pp. 165-175.
38. **Moradpour D** and Blum HE. Molecular virology and pathogenesis of hepatitis C. In: Molecular biology of the flavivirus. In: Kalitzky M and Borowski P, eds. Horizon Bioscience, Norfolk, UK, 2006, pp. 313-344.
39. **Moradpour D.** Schwangerschaftsassozierte Lebererkrankungen. In: Riemann JF, Fischbach W, Galle PR, Mössner J, Hrsg. Gastroenterologie. Das Referenzwerk für Klinik und Praxis. Georg Thieme Verlag, Stuttgart, 2007, S. 1585-1594.
40. Bartenschlager R, Long G, **Moradpour D.** Chronic hepatitis C: portrait of a silent epidemic and the etiologic agent. In: Comparative hepatitis. Weber O and Protzer U, eds. Birkhäuser, Basel, Switzerland, 2008, pp. 95-120.
41. Brass V, Gosert R, **Moradpour D.** Investigation of the hepatitis C virus replication complex. In: Hepatitis C: methods and protocols. Tang H, ed. 2nd ed. Humana Press, Totowa, NJ, 2009, pp. 195-209.
42. Blum HE and **Moradpour D.** Hepatocellular carcinoma. In: Encyclopedia of Molecular Mechanisms of Disease. Lang F, ed. Springer, Berlin, 2009.
43. Bühler S, **Moradpour D,** Bartenschlager R. New insights into the hepatitis C virus replication cycle and virus-host interactions. In: Translational research in chronic liver disease. Shaker Verlag, Aachen, Germany, 2009, pp. 17-41.
44. **Moradpour D,** Penin F and Rice CM. Replication of hepatitis C virus. In: Zakim & Boyer's Hepatology. A Textbook of Liver Disease. Boyer TD, Manns MP, Sanyal AJ, eds. 6th edition. Elsevier Science, Philadelphia, PA, 2011, pp. 97-110.
45. **Moradpour D** und Blum HE. Schmerzen im Bereich des Abdomens. In: Siegenthalers Differenzialdiagnose. Innere Krankheiten - vom Symptom zur Diagnose. Battegay E, Hrsg. 20. Auflage. Georg Thieme Verlag, Stuttgart - New York, 2013, pp. 272-317.
46. **Moradpour D** und Blum HE. Ikterus. In: Siegenthalers Differenzialdiagnose. Innere Krankheiten - vom Symptom zur Diagnose. Battegay E, Hrsg. 20. Auflage. Georg Thieme Verlag, Stuttgart - New York, 2013, pp. 752-791.
47. **Moradpour D** und Blum HE. Ikterus. In: Siegenthalers Differenzialdiagnose. Innere Krankheiten - vom Symptom zur Diagnose. Battegay E, Hrsg. 21. Auflage. Georg Thieme Verlag, Stuttgart - New York, 2017, pp. 396-431.
48. **Moradpour D** und Lammert F. Leber. In: Klinische Pathophysiologie. Blum HE und Müller-Wieland D, Hrsg. 10. Auflage, Georg Thieme Verlag, Stuttgart - New York, 2018, pp. 955-985.
49. Fraga M und **Moradpour D.** Schwangerschaftsassozierte Lebererkrankungen. In: Referenz Gastroenterologie. Riemann JF, Fischbach W, Galle PR, Mössner J, Hrsg. Georg Thieme Verlag, Stuttgart - New York, 2019, pp. 787-794.

Book edited

1. Highlights from Hepatology 2015: From Chronic Hepatitis to Hepatocellular Carcinoma. Proceedings of Falk Symposium 199. Thimme R, Chazouillères O, Llovet JM, **Moradpour D**, eds. Karger, Basel, 2016.

Publications as collaborator

1. Baur K, Mertens JC, Schmitt J, Iwata R, Stieger B, Frei P, Seifert B, Bischoff Ferrari HA, von Eckardstein A, Müllhaupt B, Geier A, and the Swiss Hepatitis C Cohort Study Group. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated interferon/ribavirin-based therapy in chronic hepatitis C patients. *Antivir Ther* 2012;17:541-547.
2. Manns MP, Gane E, Rodriguez-Torres M, Stoehr A, Yeh CT, Marcellin P, Wiedmann RT, Hwang PM, Caro L, Barnard RJ, Lee AW; for the MK-7009 Protocol 007 Study Group. Vaniprevir with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C - a randomized phase 2 study. *Hepatology* 2012;56:884-893.
3. Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer A, Mottet C, Burnand B, Froehlich F; Swiss Inflammatory Bowel Disease Cohort Study Group. Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease. *Digestion* 2013;87:212-221.
4. Maillard MH, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B, Froehlich F, Michetti P, Pittet V ; Swiss IBD Cohort Study Group. Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis. *J Crohns Colitis* 2014;8:825-834.
5. Wang H, El Maadidi S, Fischer J, Grabski E, Dickhöfer S, Klimosch S, Flannery SM, Filomena A, Wolz OO, Schneiderhan-Marra N, Löffler MW, Wiese M, Pichulik T, Müllhaupt B, Semela D, Dufour JF, Bochud PY, Bowie AG, Kalinke U, Berg T, Weber AN; East-German and Swiss Hepatitis C Virus Study Groups. A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. *Hepatology* 2015;62:1375-1387.
6. Mueller R, Ziade F, Pittet V, Fournier N, Ezri J, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A, Swiss IBD Cohort Study. Quality of life in Swiss paediatric inflammatory bowel disease patients: Do patients and their parents experience disease in the same way? *J Crohns Colitis* 2016;10:269-276.
7. Mikocka-Walus A, Pittet V, Rossel JB, von Känel R, Swiss IBD Cohort Study Group. Symptoms of depression and anxiety are independently associated with clinical recurrence of inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2016;14:829-835.
8. Lang BM, Biedermann L, van Haften WT, de Vallière C, Schuurmans M, Begré S, Zeitz J, Scharl M, Turina M, Greuter T, Schreiner P, Heinrich H, Kuntzen T, Vavricka SR, Rogler G, Beerenwinkel N, Misselwitz B; Swiss IBD Cohort Study Group. Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn's disease. *Aliment Pharmacol Ther* 2018;47:55-66.
9. Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. *Gastroenterology* 2018;154:976-988.
10. Madanchi M, Fagagnini S, Fournier N, Biedermann L, Zeitz J, Battegay E, Zimmerli L, Vavricka SR, Rogler G, Scharl M; Swiss IBD Cohort Study Group. The relevance of

vitamin and iron deficiency in patients with inflammatory bowel diseases in patients of the Swiss IBD Cohort. *Inflamm Bowel Dis* 2018;24:1768-1779.

11. Parragi L, Fournier N, Zeitz J, Scharl M, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L, Swiss IBD Cohort Study Group. Colectomy rates in ulcerative colitis are low and decreasing: 10-year follow-up data from the Swiss IBD Cohort Study. *J Crohns Colitis* 2018;12:811-818.
12. About F, Bibert S, Jouanguy E, Nalpas B, Lorenzo L, Rattina V, Zarhrate M, Hanein S, Munteanu M, Müllhaupt B, Semela D, Semmo N, Casanova JL, Theodorou I, Sultanik P, Poynard T, Pol S, Bochud PY, Cobat A, Abel L; Swiss Hepatitis C Cohort Study Group; French ANRS HC EP 26 Genoscan Study Group. Identification of an endoglin variant associated with HCV-related liver fibrosis progression by next-generation sequencing. *Front Genet* 2019;10:1024.
13. Cernoch PS, Fournier N, Zeitz J, Scharl M, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L, Swiss IBD Cohort Study Group. Lower risk of B1-to-pB3 stage migration in Crohn's disease upon immunosuppressive and anti-TNF treatment in the Swiss IBD Cohort Study. *Dig Dis Sci* 2020;65:2654-2663.
14. Becchetti C, Zambelli MF, Pasulo L, Donato MF, Invernizzi F, Detry O, Dahlqvist G, Ciccarelli O, Morelli MC, Fraga M, Svegliati-Baroni G, van Vlierberghe H, Coenraad MJ, Romero MC, De Gottardi A, Toniutto P, Del Prete L, Abbati C, Samuel D, Pirenne J, Dufour J; COVID-LT Group. COVID-19 in an international European liver transplant recipient cohort. *Gut* 2020;69:1832-1840.
15. Dietz J, Spengler U, Müllhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer KH, Berger A, Matschenz K, Buggisch P, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C; European HCV Resistance Study Group. Efficacy of retreatment after failed direct-acting antiviral therapy in patients with HCV genotype 1-3 infections. *Clin Gastroenterol Hepatol* 2021;19:195-198.
16. Ledergerber M, Lang BM, Biedermann L, Bègré S, Zeitz J, Krupka N, Rickenbacher A, Turina M, Greuter T, Schreiner P, Roth R, Siebenhüner A, Vavricka SR, Beerenwinkel N, Misselwitz B, Swiss IBD Cohort Study Group. Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management. *BMC Gastroenterol* 221;21:53.
17. Jordi SBU, Botte F, Lang BM, Greuter T, Krupka N, Auschra B, Schreiner P, Sulz MC, Biedermann L, von Känel R, Rogler G, Bègré S, Misselwitz B; Swiss IBD Cohort Study Group. Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease. *Aliment Pharmacol Ther* 2021, in press (epub May 11, 2021 | PMID 33905426).
18. Jordi SBU, Lang BM, Auschra B, von Känel R, Biedermann L, Greuter T, Schreiner P, Rogler G, Krupka N, Sulz MC, Misselwitz B, Bègré S; Swiss IBD Cohort Study Group. *Inflamm Bowel Dis*, in press (epub Jun 7, 2021 | PMID 34096587)

Other publications (selection)

1. Coordinator and first author. Swiss Association for the Study of the Liver (SASL)-Swiss Society for Infectious Diseases (SSI) Expert Opinion Statement on the Treatment of Chronic Hepatitis C - September 2014 Update.

2. Co-coordinator and last author. Swiss Association for the Study of the Liver (SASL)-Swiss Society for Infectious Diseases (SSI) Expert Opinion Statement on the Treatment of Chronic Hepatitis C - September 2015 Update.
3. Co-coordinator and last author. Swiss Association for the Study of the Liver (SASL)-Swiss Society for Infectious Diseases (SSI) Expert Opinion Statement on the Treatment of Chronic Hepatitis C - January 2016 Update.
4. Co-coordinator and second author. Swiss Association for the Study of the Liver (SASL)-Swiss Society for Infectious Diseases (SSI) Expert Opinion Statement on the Treatment of Chronic Hepatitis C - September 2016 Update.
5. Co-coordinator and second author. Swiss Association for the Study of the Liver (SASL)-Swiss Society for Infectious Diseases (SSI) Expert Opinion Statement on the Treatment of Chronic Hepatitis C - March 2017 Update.
6. Co-coordinator and second-to-last author. Swiss Association for the Study of the Liver (SASL)-Swiss Society for Infectious Diseases (SSI) Expert Opinion Statement on the Treatment of Chronic Hepatitis C - June 2017 Update.
7. Co-coordinator and second-to-last author. Swiss Association for the Study of the Liver (SASL)-Swiss Society for Infectious Diseases (SSI) Expert Opinion Statement on the Treatment of Chronic Hepatitis C - August 2017 Update.
8. Co-coordinator and second-to-last author. Swiss Association for the Study of the Liver (SASL)-Swiss Society for Infectious Diseases (SSI) Expert Opinion Statement on the Treatment of Chronic Hepatitis C - November 2017 Update.
9. Coordinator and first author. Swiss Association for the Study of the Liver (SASL)-Swiss Society for Infectious Diseases (SSI) Expert Opinion Statement on the Treatment of Chronic Hepatitis C - August 2018 Update.
10. Coordinator and first author. Swiss Association for the Study of the Liver (SASL)-Swiss Society of Gastroenterology (SSG)-Swiss Society for Infectious Diseases (SSI) Expert Opinion Statement on the Treatment of Chronic Hepatitis C - January 2021 Update. Available at www.sasl.ch, www.sggssg.ch and www.sginf.ch.